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ABSTRACT 
 
JDTic is a KOR selective antagonist belonging to the trans (3R,4R)-dimethyl-4-(3-
hydroxyphenyl)piperidine scaffold, which is known as an opioid antagonist pharmacophore for 
all receptors. A pharmacophore has been designed based on the crystalline structure of JDTic 
inside the KOR. In this study, by screening in silico over 1.9 million commercially available 
small molecules, we report a new class of MOR and KOR antagonist ligands which is 
representative of the successful outcome of virtual high throughput screening (HTS). To create 
these we applied a combination docking method that integrates ligand and receptor centric 
virtual screening search techniques in order to screen libraries of commercial compounds. 
Compound (1) produced a concentration-dependent inhibition of specific [3H]-U69,593 
(KOR) binding with a Ki value of 445 nM. Compound (1) also inhibited specific [3H]-
DAMGO (MOR) with Ki values 44 nM, while no binding affinity toward DOR was observed. 
To characterize the relative efficacy and potency of compound (1), it was assayed in a 
GTPγ[35S]S functional assays. 
Compound 1 was tested for its ability to stimulate [35S]GTPγS binding mediated by the 
KOR and MOR. Compound (1) showed no activation of the G protein (i.e., was an antagonist) 
for both KOR and MOR in a GTPγS assay compared to full agonists U69,593 (KOR) and 
DAMGO (MOR). Antagonism was confirmed by running GTPγS assays with a fixed amount of 
agonist against a dilution series of compound (1) and known opioid antagonist naloxone 
hydrochloride. Both compound (1) and naloxone were able to antagonize 20 nM U69,593 
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(KOR) or 200 nM DAMGO (MOR) agonist activity, with IC50 values of 511.2+/-175.3 nM and 
3.229+/- 0.942 nM, respectively, for KOR, and 774.9+/-107.3 nM and 11.78+/-1.70 nM, 
respectively, for MOR. 
We developed an efficient six-step synthesis of a compound 1 starting from dimethyl 
itaconate utilizing a sequence of cyclization, reduction and coupling reactions. We also 
developed an easy derivatization approach utilizing convergent analog synthesis to study 
SAR around the lead structure. 
Further SAR optimization led to the discovery of several low nanomolar binding affinity 
antagonists with preference for one of the opioid receptors. This new series of compounds 
can be further evaluated in in-vivo models to develop future drug candidates. 
Radioligand binding assays for opioid and cannabinoid receptors have been a useful tool 
for the discovery of novel agents. Bioassay-guided fractionation of the Russian Sage Perovskia 
atriplicifolia resulted in the isolation of four known flavonoid derivatives, 5-hydroxy-3’,4’,6,7-
tetramethoxy flavone (1), 5,7-dihydroxy-3’,4’,6,-trimethoxy flavone (2), 5-hydroxy-4’,6,7-
trimethoxy flavone (3) and 5,7-dihydroxy-4’,6-dimethoxy flavone (4). The structures of these 
compounds were established on the basis of extensive 1D and 2D NMR spectroscopic analysis 
and mass spectrometric data. Compound 1, 3, 4 showed displacement of radioligand for the δ 
opioid receptor with IC50 values ranging from 6.1 to 49.5 μM. These studies have important 
implications in understanding non-nitrogenous δ opioid receptor ligands. 
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CHAPTER ONE: 
MOLECULAR MODELING AND SAR OF DESIGNED OPIOID ANTAGONIST 
I.1 INTRODUCTION 
1.1 G-Protein Coupled Receptors 
G protein-coupled receptors (GPCRs) are a large category of integral membrane proteins 
that all have seven transmembrane helices connected by alternating extra- and intra- cellular 
loops. These play a critical role in cell-cell communication. Extra-cellular loops, which vary 
among the different types of GPCRs, contribute to ligand recognition and binding, whereas 
coupling to particular G-proteins is determined by the intra-cellular loops [1, 2]. G-protein 
coupled receptors are only found in eukaryotic organisms such as animals, plants, fungi and 
protists [3], and are associated with a variety of physiological processes including autonomic 
nervous system transmission, regulation in immune system activity and inflammation, and 
behavioral and mood regulation [4]. For this reason, GPCRs are common drug targets in the 
pharmaceutical industry, accounting for approximately 40% of new drugs [5]. GPCRs evolved to 
sense a number of extracellular signals such as photons, ions, monoamines, nucleosides, lipids, 
peptides and proteins [6]. These extracellular signals transmit through GPCRs across the plasma 
membrane through activation of G-proteins and arrestins. There are a variety of ligands, such as 
hormones and neurotransmitters that bind and activate these receptors. These ligands vary in size 
and include small molecules, peptides, and large proteins. Depending on the ligand and the 
receptor, there are numerous different binding domains found in the N terminal and in the 
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transmembrane domain, as well as a number of allosteric binding sites, as well as a number of 
allosteric binding sites. 
Figure 1. GPCR signal cascade
 
G-proteins are heterotrimeric, consisting of 3 subunits named α, β, and γ, and bind 
guanine nucleotides to their α-subunit, catalyzing the hydrolysis of guanosine triphosphate 
(GTP) to guanosine diphosphate (GDP) upon agonist binding (Figure 1) [7]. Coupling of the 
GPCR to the G- protein results in dissociation of the α-subunit from the βγ-subunit, and the 
βγ-subunit can then activate a number of different effectors, such as enzymes or ion channels 
(Figure 1) [8]. The α-subunit has a role in determining receptor specificity and can also 
influence the efficiency of interactions of the βγ-subunit [8]. On the basis of G-protein 
coupling preference, GPCRs can be classified into 4 major categories: Gαs-, Gαi/o-, Gαq/11-, 
and Gα12/13-coupled receptors [9]. Almost all agonists that have an analgesic action are 
coupled to Gαi/o proteins [8]. The Gαi and Gαo proteins inhibit adenylate cyclase, while Gαs 
stimulates production, and of the effectors implicated in signaling mechanisms for opioid 
receptors, inhibition of adenylate cyclase and subsequent decrease in intra-cellular cyclic 
adenosine monophosphate (cAMP) concentrations is the best studied [7].
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GPCRs can also signal through G-protein independent mechanisms, the best 
characterized of which is the GPCR kinase (GRK)/β-arrestin pathway [10]. Mammals express 
seven GRK isoforms [10]. Isoforms GRK1 and GRK7 are confined to the retina, GRK4 has 
limited cellular distribution with high expression localized in the testes, and GRK2, GRK3, 
GRK5, and GRK6 are ubiquitously expressed [10]. In the first step of the pathway, serine and 
threonine residues of the third intra-cellular loop and the carboxy terminus region of the 
agonist-bound receptor are phosphorylated by a GRK (Figure 2). For some GPCRs, agonist 
activation and phosphorylation by a GRK are enough to cause the G-protein to become 
decoupled from the receptor itself, leading to receptor desensitization, however many GPCRs 
require the additional step of recruitment of proteins called arrestins [10].. 
Figure 2. GRK/ β-arrestin mechanism
 
1.1.1 Opioid receptors 
Opium is an extract of the poppy plant, Papaver somniferum. In the second century, 
Galen, a Greek physician, administered opium to patients for the relief of pain, asthma and 
congestive heart failure. In 1804, the German chemist Serturner isolated morphine (1) from 
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opium. However, it was not until 1973 that morphine (1) was confirmed to target opioid receptors 
[11].  The classification of opioid receptors has evolved along with research and understanding of 
them [12–14]. The existence of a single opioid binding site was first proposed in 1954 by Beckett 
and Casy [15]. By the mid-1960s, Portoghese [16] and Martin [17] had both suggested that there 
were multiple opioid receptors. Based on studies in the 1970s [18, 19], multiple types of opioid 
receptors were classified. The three opioid receptors Martin proposed based on the 
pharmacological profile of various of opioids were the µ, к, and σ receptors with morphine (1), 
ketocyclazocine (2), and SKF-10,047 (N-allylnorcyclazocine) (3), respectively, as the prototypical 
ligands (Figure 3). The δ-receptor, a different type of receptor, was proposed later after the 
discovery of enkephalins [20]. It is now accepted that there are three distinct types of opioid 
receptors, the µ, к, and δ-receptors. The σ-receptors proposed by Martin are not considered opioid 
receptors because their effects are not reversed by opioid antagonists [21]. The existence of other 
opioid receptors has been suggested, but they are not generally accepted [22]. The µ, к, and δ-
receptors have all been cloned; research attempting to clone these receptors led to the discovery of 
another receptor, named the opioid-receptor-like receptor (ORL 1) by Mollereau et al [23]. While 
it has some of the same physiological effects as opioid receptors, it does not display affinity to 
opioid receptor ligands such as naloxone. 
 Figure 3. Agonist used by Martin to define δ, к, and µ. 
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Evidence shows that the effects of opioid receptors come from the G-proteins coupled to 
these receptors [24, 25]. Cloned opioid receptors show a structure consistent with this receptor 
super-family. The G-proteins coupled to opioid receptors are heterotrimeric, meaning they have 
three parts, the α, β, and γ sub-units. The sub-unit binds with guanine nucleotides to catalyze the 
hydrolysis of GTP to GDP. G-proteins are the key part of a variety of different types of 
receptors, including opioid receptors. There are many different forms of G-proteins, including Gs, 
which stimulates adenylyl cyclase, and Gi and Go, which both inhibit adenylyl cyclase. Because 
pertussis toxin inhibits Gi and Go by ADP ribosylation of the sub-unit, and cholera toxin 
activates Gs, these toxins can be used to test for involvement of the different G-proteins in the 
transduction mechanisms of opioid and other receptors. Through studies of the effector systems 
for opioid receptor transduction mechanisms, it has been shown that an opioid agonist binding 
with the receptor inhibits adenylyl cyclase [24–28], and decreases intracellular cAMP in a 
number of different tissues. Either Gi or Go is involved in opioid receptor transduction 
mechanisms, as shown by pertussis toxin sensitivity of opioid inhibition of adenylyl cyclase. 
Research demonstrates that all three types of cloned opioid receptors show this adenylyl cyclase 
inhibition, while some studies also suggest that µ and δ-receptors can stimulate adenylyl cyclase 
under certain tissues [29, 28, 25]. There is dispute over the effect of -opioid receptors on 
phosphatidylinositol turn over in different tissues, but δ and µ receptors do not appear to have 
any effect on phosphatidylinositol turnover in neuroblastoma cell lines NG108-15 and SK-N-SH 
[30]. G-proteins also allow opioid receptors to be coupled to ion channels [26-28, 31], and all 
three receptor types decrease Ca
+2
 current. Because pertussis toxin stops the effect of opioids on 
Ca
+2
 current, and G-proteins are involved in the linking of calcium channels with opioid 
receptors, it stands to reason that Gi or Go is involved. Coupling opioid receptors with potassium 
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channels shows similar effects to those resulting from coupling with calcium channels. Evidence 
indicates that these results achieved with ion currents come from G-protein coupling of ion 
channels and with the opioid receptors, rather than being the result of adenylyl cyclase inhibition 
[31]. 
The binding of an agonist with an opioid receptor seems to activate the extracellular 
signal regulated kinase (ERK) cascade [28]. The ERK cascade has three intracellular kinases, 
known as the mito-gen-activated protein kinase, the MAPK kinase, and the MAPK homolog. 
This process appears to be connected to either Gi or Go [28]. 
1.2 Receptor Subtypes 
Before the opioid receptors were cloned, pharmacological assays suggested the existence 
of subtypes of three receptor types [28, 32]. However, cloning of the receptors has only shown 
one subtype of each type of receptor and the existence of receptor subtypes is still the subject of 
dispute among researchers. Research using functional assays and binding studies suggests that 
there are two subtypes of δ-opioid receptors [28, 33, 34], characterized by the ligands selective 
for each of the proposed subtypes. Subtype δ1 is stimulated by encephalin analog DPDPE (4) and 
DADLE (5) with antagonism by naltrindole analog BNTX (7-benzilidenenaltrexone) (6) [35] 
and the affinity label DALCE (7) [36], while subtype δ2 is stimulated by [D-Ala
2
] deltorphin II 
(8) and DSLET (9), with antagonism by benzofuran- and naltrindole analog naltriben (10) [37] 
and irreversible antagonism by naltrindole iso- thiocyanate (NTII) (11) (Figure 4). Rothman and 
coworkers suggested a different classification for δ-opioid receptor subtypes, based on whether 
or not they were associated with a µ-δ receptor complex [38]. Using irreversible ligands FIT or 
(+)-transSUPERFIT, the researchers selectively acylated dncx receptors and depleted the 
membranes of dcx receptors using µ-receptor affinity label BIT [39-41]. The researchers found 
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evidence from pharmacological and binding studies indicating that dncx receptors corresponded to 
δ1 receptors, and dcx to δ2 receptors, and antisense oligonucleotides differentially affect the two 
subtypes [42-44]. The cloned δ-opioid receptor shows signs of belonging to the δ2 subtype, based 
on pharmacological studies [45]. Neither 
3
H-DPDPE nor 
3
H-[D-Ala2] deltorphin II show binding 
in δ-receptor knockout mice, suggesting that the subtypes do not result from different gene 
products and agonists selective for the δ-receptor still show analgesic properties, which indicates 
that there is another δ-like system [46]. Researchers have also suggested the existence of 
multiple subtypes of µ opioid receptors [28, 47]. The suggested µ1 subtype was characterized as 
a high-affinity binding site for both peptide and non-peptide opioids, while the proposed µ2 
subtype was considered the “traditional” m-binding site [48]. It is believed that µ1 receptors 
comprise ~20% of µ-specific binding in rat brain membranes; these µ1 receptors are studied 
using derivatives of naloxone [47, 49]. Pasternak and coworkers, since the cloning of opioid 
receptors, have suggested several splice variants of the µ opioid receptor [50, 51]. In addition, 
researchers have proposed the existence of at least three different subtypes of к opioid receptors. 
The  receptor subtypes were first suggested as a result of research in the 1980s, but there was 
much dispute over exactly what the difference were between the subtypes [28, 52]. More 
recently, further research has indicated the existence of к1 and к2 subtypes, differentiated by 
whether or not they are sensitive to the к-selective arylbenzacetamide U50,488 (12) [53]. Cloned 
к opioid receptors seem to be к1 subtypes, due to the fact that -receptor knockout mice show no 
analgesic response to U50,488 [54]. In order to check for residual к2 binding sites, researchers 
used knockout mice for each of the opioid receptors and mice lacking all three receptors [55]. 
The research showed that all residual к2 binding could be attributed to  and  receptors, and the 
mice lacking all three receptors showed no residual binding of [3H]bremazocine (13). This 
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suggests that no other gene is involved in the binding of this opioid ligand. Based on research 
using naloxone benzoylhydrazone, Nal(Bzo)H another subtype, к3, has also been suggested [56]. 
Figure 4. Ligand used to characterize opioid receptor subtypes 
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1.3 Receptor Dimerization 
Dimerization is a method for controlling signals from several types of plasma membrane 
receptors. Dimerization has been best studied in receptor tyrosine kinases but has also been 
found to occur in several GPCRs, including opioid receptors, where heterodimerization is known 
to change the properties of opioid ligands and affect receptor trafficking [57-59]. 
Heterodimerization of opioid receptors has also been found to occur with other classes of 
GPCRs, including the NK1 and 2-adrenergic receptors [59-61]. A problem arises in trying to 
determine whether or not opioid heterodimers or other opioid GPCR dimers occur in vivo, 
though new studies on bivalent ligands that selectively target heterodimers may help to answer 
this question [62, 63]. Studies using opioid receptor knockout mice suggest that 
heterodimerization does in fact occur, at least with the opioid receptors. For example some 
MOP-R-specific analgesia is lost in the DOP-R-deficient mice [64]. This suggests that the 
MOP/DOP receptor dimer no longer exists in the knockout mice. 
1.4 Opioid receptor structure  
Opioid receptors belong to the class A (Rhodopsin) family of Gi/Go-protein protein 
coupled receptors [7]. Based on the model of this family of receptors, the receptors contain 
extracellular N-terminal domain, seven putative transmembrane helical domains connected by 
three extracellular domains, three intracellular domains, and an intracellular C-terminal tail 
possibly forming a fourth intracellular loop with its putative palmitoylation site(s). The opioid 
receptors share a high degree of similarity in their structural folds, with 67% similarity for the 
NOP compared to the other receptors, and 76% similarity between the MOP and DOP [65]. This 
can be expected due to the high sequence identity of the TM regions. The largest difference 
between the opioid receptors was found in their N and C termini as well as their extracellular 
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loops [66]. The highest sequence homology between opioid receptors is in TM2, TM3, and TM7. 
Intracellular loops also show high similarity; the third intracellular loop is thought to be involved 
in interaction with G-proteins [240]. On the other hand, second and third intracellular loops, 
TM1 and TMs 4-6 show less conservation. Potential sites for possible posttranslational 
modification have been identified on the receptors, such as two potential kinase C 
phosphorylation located in the C-terminus, and a third site found in the third intracellular loop 
[240]. In addition, two possible glycosylation sites were found located on the N- terminal.  
1.5 Opioids, Receptors, and the Treatment of Pain 
One focus for studies on new biological mechanisms is the development of better methods 
for pain management, which are sorely needed in medicine today. All pain is the result of 
stimulation of nociceptors, the nerve receptors responsible for pain sensations, which are located 
throughout the body and can be activated by physical or chemical stimulation released from 
surrounding tissues (e.g. histamine or lactic acid) [67]. Pain is perceived differently, however, by 
different individuals and based on experience and other factors that are not directly related to the 
central nervous system [68]. Severe pain is a common reason cited for workers compensation 
claims, and pain management is one of the most common reasons for medical office visits [69]. 
The most common methods of treating severe, chronic pain are opium alkaloids like morphine 
and similar drugs [7]. In the last two decades more than $2.5 billion has been spent by the 
pharmaceutical industry trying to identify new pain medicines. Despite these efforts, morphine 
and related compounds still remain the first- line therapy for moderate to severe pain in the U.S. 
Furthermore, many new drugs in the marketed are alternative dosage forms of classical opioids 
(Figure 5). Opioid drugs, however, have many unpleasant and detrimental side effects, including 
respiratory depression, constipation, tolerance, and dependence, which make them inadequate for 
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chronic use [7]. Opioid drugs block pain by targeting the MOR as agonists. The negative side 
effects of opioid drugs are directly caused by the activation of the MOR. These include a high 
percentage of patients with gastrointestinal issues due to the presence of μ opioid receptors 
located in the intestines [69]. Since patients do not experience tolerance to this side effect of 
opioid drugs, continuous use is associated with chronic constipation and related GI problems, 
which are known as opioid bowel dysfunction [7]. Respiratory depression is another severe side 
effect of opioid drugs, caused at least in part by interaction of opioids with the respiratory center 
in the brain stem, causing a decrease in the sensitivity of the body to rising carbon dioxide levels 
in the blood, leading to depressed respiration [70]. This side effect can be managed by proper 
titration of drug doses, but respiratory depression is the primary reason for death in cases of 
overdose [71]. Another detrimental effect of opioid use is dependence and tolerance resulting 
from continued use. Tolerance occurs when exposure to a drug results in its decreased 
effectiveness with time then larger doses required to get the same level of effect from the drug 
[7]. While the exact cause of tolerance is unknown, it has been attributed to the desensitization 
and internalization processes that take place in the GRK/γ-arrestin signaling pathway. 
Dependence is when a patient experiences withdrawal symptoms when drug use is suddenly 
stopped or in case of significant reduction in the dose of the opioid or administration of an opioid 
antagonist [72]. Addiction results from dependence and tolerance and occurs when a patient uses 
drugs compulsively to avoid withdrawal symptoms, regardless of the harmful effects the drugs 
have on the body. Constipation is the most common side effect of long-term narcotic. The 
frequency of these side effects is very high (40–50% or more in patients receiving opioids [73–
75]) and can become the limiting factor in opioid use. These effects are mediated predominantly 
by -receptors in the bowel [76]. The effects begin with delayed food digestion in the small 
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intestine and decrease in peristaltic waves in the large intestine resulting in the retention of bowel 
contents. This is compounded by the enhanced tone of the anal sphincter and the reduction of the 
reflex relaxation in response to rectal distension. Tolerance does not usually develop to this side 
effect, and the patient on long-term opioid therapy remains chronically constipated [76].  
Figure 5. Most commonly used clinical agent 
 
1.5.1 Therapeutic Potential of MOR Selective Agents 
It has been recognized that the analgesic effects and also the unpleasant side effects (such 
as addiction, respiratory depression, and tolerance) of most opioid drugs available in the market 
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are primarily due to their interaction with the µ opioid receptor (MOR) [77-79]. In order to 
counteract these negative effects, studies look to MOR antagonists. In addition to treating opioid 
dependence, they are also used in the treatment of alcoholism [80], and have potential for 
treating a variety of other conditions such as psychosis [81], obesity [82], and Parkinson’s 
disease [83]. However, the structure-function relationship of the MOR is still not fully 
understood, because scientists lack potent, nonpeptidyl antagonists that are highly selective for 
the MOR. The only available MOR antagonists are only slightly selective for the MOR over the 
other opioid receptors, such as: naloxone (28) and naltrexone (27) [84]. Other antagonists 
selective for the MOR are irreversible, binding covalently with the receptor; these include β-
FNA and clocinnamox. There are highly selective, reversible MOR antagonists, but they are 
conformation-constrained peptides, such as CTOP and CTAP [85-88]. In vitro and in vivo 
studies have shown that they show high selectivity for the MOR, and they are metabolically 
stable. However, since they are peptides, they have limited bioavailability and therefore are not 
very useful in most medical studies [85-88]. Non-peptide ligands are better suited as antagonists 
for pharmacological studies because they are better able to penetrate the central nervous system, 
and show less metabolic breakdown than peptide antagonists. For this reason, it is necessary to 
create a potent, reversible, nonpeptidyl antagonist that is highly selective for the MOR.  
1.5.2 Therapeutic Potential of KOP Receptor Selective Agents 
Because of the issues which occur with drugs targeting the MOR, studies are looking into 
the possibility of using opioid ligands selective for other receptors. Ligands selective for the к 
opioid receptor have shown utility as analgesics, and do not show the same negative side effects, 
such as respiratory depression and gastrointestinal problems, that are caused by drugs targeting 
the MOR
 
[90]. KOR agonists do have their own negative side effects, specifically mood 
disorders like dysphoria [89], a negative effect that is the opposite of euphoria; however, there is 
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some suggestion that KOR agonists which only work on the peripheral nervous system can have 
analgesic effects without the negative consequences
 
[90]. The body’s endogenous KOR agonist, 
dynorphin, is produced as a result of stress. The activation of the KOR by DYN, a KOR agonist, 
is believed to be partly responsible for depression and similar mood disorders [91]. This suggests 
that a KOR antagonist, which would prevent activation of the KOR, could be useful in treating 
these disorders. There have been studies on the effectiveness of various KOR-selective 
antagonists, including nor-binaltorphimine (norBNI ), GNTI, and JDTic (Figure 6), in treating 
depression in rodents, and they have shown some good results [92]. The problem with these 
studies is the fact that the KOR-selective antagonists show long-term prevention of KOR 
activation, sometimes up to 56 days [93]. Non-selective antagonists do not show these long-term 
effects, and the exact cause for this problem is not yet understood. It is known that it is not the 
result of covalent binding of the antagonist to the KOR, changes to the receptor caused by the 
antagonist, or by accumulation in the lipid membranes. The Chavkin group did find that the long 
duration of selective antagonist action is positively correlated to activation of c-Jun N-terminal 
kinase (JNK), although how JNK activation leads to long-term KOP receptor inactivation 
remains unclear [93, 94]. Thus, the search for selective KOP antagonists with improved 
pharmacokinetic and pharmacodynamic properties continues. 
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Figure 6. Selective KOR antagonists
 
1.5.3 Therapeutic Potential of DOP Receptor Selective Agents 
The most important aspect of the δ receptor is its antinociceptive activity, without the side 
effects caused by activation of the  receptor. δ receptor agonists also show a relation to 
inflammatory and neuropathic pain [95]. One type of  receptor plays an important role in 
modulating the µ receptor through its close association with the µ receptors. Agonist activation 
of these  receptors makes the analgesic activity of µ agonists more effective, and antagonist 
activation can decrease the detrimental side effects associated with the µ receptor [96, 97]. The  
antagonists can prevent the development of tolerance to the analgesic effects of morphine [98]. 
Both agonists and antagonist show the ability to reverse respiratory depression caused by µ 
agonists. The  receptors also show potential in the treatment of abuse of other drugs, such as 
cocaine, alcohol and amphetamines. Some studies have shown that  receptor ligands can 
decrease the effects of cocaine, and for this reason could be useful for treating cocaine abuse 
[99]. Other studies have shown that  ligands have effects in treating methamphetamine abuse as 
well [100,101]. 
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1.6 SAR of Non-Peptidic Opioid Ligands 
There has been extensive research focused on the development of peptidic ligands for the 
opioid receptors, while a large body of research has been were also concerned with the 
development of morphine based small ligands. Ligands with opioid activity are structurally 
diverse, starting with rigid multi-cyclic scaffolds such as morphine (1) to flexible acyclic 
scaffolds such as methadone. There are several nonpeptide opioids which have been developed, 
and they fall into one of the five chemical classes: 4,5α-epoxymorphinans, the morphinans, the 
benzomorphans, phenylpiperidines, and acyclic opioids. Conceptually these diversified chemical 
classes can be related to each other by envisioning a systematic dismantling of morphine nucleus 
(Figure 7).  
Figure 7. Systematic dismantling of morphine [102]. 
  
Most of the opioid ligands belong to the 4,5α-epoxymorphinans class, which include several 
natural products isolated from the opium poppy including Morphine (1) and codeine (14), which 
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both show analgesic activity in contrast to thebaine (25) (Figure 8). Masking the 3-and 6-
hydroxyl group of morphine led to 3,6-diacetylmorphine (heroin, 26), which increases the 
lipophilicity and penetration of the blood-brain barrier [104]. Methylation of the phenolic 
hydroxyl group gave codeine, which has less activity as an analgesic and lower risk of physical 
dependence than morphine [23, 103]. While all portions of the morphine molecule have been 
modified, the focus has been in three regions: the basic nitrogen, the phenol, and the C ring. 
Some of the structure activity relationship (SAR) for 4,5α-epoxymorphinans is summarized in 
Table 1[105].  
 
Figure 8. 
Numbering of Morphine, 25 and other alkaloids found in opium, 26 early synthetic analog of morphine  
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Table 1. Selected SAR summary for morphine. 
Derivative  
 
Modification Effect on the  
Analgesic activity 
Codeine 3-OH to 3-OMe Decrease  
3-acetylmorphine 3-OH to 3-OAc Decrease 
Dihydromorphine 7,8-dihydro Increase  
Dihydrocodeine  3-OH to 3-OMe and 7,8-dihydro Decrease  
Methoxymethyl-dihydromorphin 3-OH to 3-CH2OCH3 and 7,8-dihydro Decrease 
3-benzylmorphine 3-OH to CH2C6H6 Decrease 
3-benzyldihydromorphine 3-OH to CH2C6H6 and 7,8-dihydro Decrease 
Hetrocodeine 6-OH to 6-OMe Increase 2 times 
6-acetylmorphine  6-OH to 6-OAc Increase 4 times  
Morphinone 6-OH to =O Decrease  
dihydromorphinone 6-OH to =O and 7,8-dihydro Increase 1.5 times 
Dihydrocodeinone 3-OH to 3-OMe, 6-OH to =O and 7,8-
dihydro 
Increase 6 times 
Methyldihydromorphine  5-methyl, 6-OH to =O and 7,8-dihydro Increase 50 times 
Dihydroheroin 3,6-OH to 3,6-OAc and 7,8-dihydro Decrease 
NorMorhpine  N-Me to N-H Decrease 
N-propylnormorphine N-Me to C3H7 Nearly abolished 
N- isopropylnormorphine N-Me to CH(CH3)2 Nearly abolished 
N-allylnormorphine N-Me to CH2CH=CH2 Nearly abolished 
N-methylallylnormorphine N-Me to CH(CH3)CH=CH2 Nearly abolished 
N-isobutylnormorphine N-Me to CH2CH(CH3)2 Nearly abolished 
 
The most important modification to note is that replacement of the basic nitrogen 
substituent dramatically affects functionality; N-phenylethyl and N –Me are agonists while N-
cyclopropylmethyl (naltrexone, 27) and N-allyl (naloxone, 28) are antagonists. Alteration of 
position 14 to 14β-hydroxyl through oxidation of thebaine enhances potency. The 14β-
hydroxylated derivative oxycodone (16) and oxymorphone (30) are potent analgesics [106]. 
While the natural leavorotatory isomer of thebaine has no analgesic effect, it is an important 
precursor for the synthesis of codeine as well as 6,14-endoetheno opiates. Diels-Alder reaction of 
thebaine with different electrophile compounds produced derivatives that are more potent than 
morphine such as etorphine (31), which is 1000 times more potent than morphine as an analgesic 
[107]. Replacement of the N-methyl with N-cyclopropylmethyl for 6,14-endoetheno produces 
two derivatives, diprenorphine (32), and buprenorphine (33). The only difference between these 
19 
 
derivatives is the alkyl group attached to C19 (figure 9). Diprenorphine (32) is a non-selective 
antagonist for opioid receptors. Buprenorphine (33), on the other hand, is a partial agonist for the 
µ opioid receptor and a к receptor antagonist [108]. This pharmacological profile provides 
several benefits to buprenorphine use in a clinical setting. Because it is only a partial agonist, it 
does not cause as severe respiratory depression as full agonists, and it has less potential for 
abuse. This also makes it useful for treating withdrawal symptoms in patients with opiate 
addictions; however, as a partial agonist buprenorphine can sometimes cause withdrawal 
symptoms [108].          
Figure 9. 
6,14 –endoetheno derivative of thebaine; Etorphine, Diprenorphine and Buprenorphine
 
1.6.1 Morphinans 
The structure of morphinans, as well as their derivation, is different from that of 
morphine and other 4,5α-epoxymorphinans. Morphinans do not have the 4,5α-ether bridge 
characteristic of morphine, and, unlike morphine, are not generally derived from naturally 
occurring alkaloids. The properties of morphinans vary greatly depending on their configuration 
[109]. Levorphanol (34), which has the same configuration as morphine, has analgesic properties 
almost five times as potent as morphine [109], suggesting that the analgesic activity is limited to 
the levo isomer. Dextrorphan (35), on the other hand, has no opioid effect, while its 3-methyl 
ether, dextromethorphan (36) has antitussive properties [110]. Dextromethorphan and other 
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morphinan derivatives with an unsubstituted 6-position have the C-ring in the chair 
conformation, unlike morphine, which has its C-ring in the boat conformation [111]. 
The morphinans show very similar properties to morphine derivatives when it comes to 
substitution on the nitrogen [112]. For example, replacing the N-methyl with an allyl or 
cyclopropylmethyl creates the µ antagonists levallorphan (37) and cyclorphan (38), respectively. 
Cyclorphan also shows antinociception at the δ and к receptors. When the cyclobutylmethyl (39) 
is substituted for the cyclopropylmethyl, it becomes an agonist for к and µ but has no effect on δ 
[113]. 
Figure 10. Morphinan derivatives
 
1.6.2 Benzomorphans 
The benzomorphans differ from morphinans in that they lack the C-ring, resulting in a 
simplified structure. Various benzomorphans have been synthesized with different alkyl 
substituents at the 5- and 9- positions [114]. The alkyl group located at 9 can either be at 
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orientation α or β (figure 11). When the alkyl group is oriented at α, the substituents located at 5 
and 9 are cis, whereas when the alkyl group is oriented at β, they are trans. The configuration 
with alkyl groups oriented at β results in more potent compounds than those with alkyl groups 
oriented at α [114]. The properties, either agonist or antagonist, vary based on the content of the 
alkyl group [115]. For example WIN 44,441 (40) is an antagonist for both к and µ receptors 
[116]. The benzomorphans show similar effects to morphine derivatives and morphinans when 
substitutes are made on the nitrogen [117]. However, the orientation of the alkyl group located at 
9 has an effect on the agonist or antagonist properties of the compound [118]. The orientation of 
the alkyl group affects the potency of agonist activity more than that of antagonist activity. These 
benzomorphan derivatives, with the exception of pentazocine (41), are not useful in a clinical 
setting because of their dysphoric and psychotomimetic effects [119]. 
Figure 11. Benzomorphan derivatives
 
1.6.3 Piperidine derivatives 
Phenylpiperidines are further simplified from the structure of benzomorphans, in that the 
B-ring is eliminated, making the phenylpiperidines more flexible than the other similar 
compounds. One example is meperidine, which functions as an analgesic. Although it is only 10-
20% as potent as morphine, and has much lower affinity for the opioid receptors, meperidine 
(42) penetrates the brain more easily and can reach concentrations in the brain of to 600 times 
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those of morphine [120]. Piperdine analgesics can be divided up based on their substitution at C4. 
For example, with the 4-arylpiperidines, the second substituent can be attached to the piperidine 
ring either by a carbon, as in meperidine, or by an oxygen, as in α (43) and β (44) prodine. 
Figure 12. Example of piperidine derivatives with different substituentson C4
 
In peperidine derivatives, the phenyl ring can have either an axial or equatorial 
orientation. The favorable position of the phenyl ring depends on the second substituent on C4. If 
this substituent has oxygen, then the activity of the compound is not affected by the orientation 
of the phenyl ring, as has been found in meperidine derivatives [121, 122]. However, if this 
substituent does not contain oxygen, then the orientation of the phenyl ring determines whether 
the compound shows agonist or antagonist activity, rather than the substitution on the basic 
nitrogen [123,124], as seen for the previous families. When the phenyl ring is in the axial 
position, the compound shows agonist activity. However, the introduction of a 3β-methyl group 
changes the orientation of the phenyl ring to equatorial, producing antagonist activity [125]. 
Fentanyl (18), an analgesic with up to 500 times the potency of morphine, is another 
piperidine derivative [126]. It is an example of a 4-anilidopiperidine, which differs from other 
piperidine derivatives in that a nitrogen has been inserted between the phenyl ring and the C4 of 
the piperidine ring. In these compounds, the preferred orientation for the anilido group is 
equatorial [127], while β orientation is favorable for the phenyl ring. 
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Many studies have been done with modifications to fentanyl. The introduction of a polar 
carbon substituent at C4 creates a compound even more potent than fentanyl itself [128]. Adding 
a methyl group to the three position gives a dextro and levo isomer. The dextro isomer is 120 
times more potent than the levo isomer [129]. The absolute stereochemistry of the dextro isomer 
is 3R,4S [129]. 
1.6.4 Other Opioids 
Methadone (20) and its derivatives are ring-opened derivatives of the phenylpiperidines 
[7]. Methadone is used in a clinical setting to manage opiate addiction, because it has similar 
analgesic effects but a longer duration of action. This makes it easier to maintain sufficient blood 
concentrations and prevent withdrawal symptoms [130]. With methadone derivatives, 
replacement of the N-substituent generally reduces the potency of the analgesic effect [131]. 
Another class of opioid ligands are arylacetamides, which were discovered in 1982 [132]. 
The highly selective KOP agonists used for radioligand binding assays, U50,488 (12) and 
U69,593 (45), are arylacetamides [134]. SNC 80 (46), discovered in 1994, belongs to the 
benzhydrylic piperazine class and functions as a δ agonist [135]. JDTic (24), also recently 
discovered, is an extremely potent and highly selective KOR antagonist that belongs to yet a 
different class of opioid ligands known as tetrahydroisoquinolines [136]. Even more recently, 
other selective KOP antagonists have been found in the 8-azabicyclo[3.2.1]octan-3-yloxy-
benzamide structural class, including the short-acting antagonists AZ-MTAB (47) and AZ-ECPC 
(48), and other similar compounds [137-140]. N-alkyl-octahydroisoquinolin-1-one-
8carboxamides (49) have also been reported as selective for KOR [141, 142], and PF-4455242 
(50), a byphenylsulfonamide, is a selective KOR antagonist which shows promise for treating 
depression [143]. Salvinorin A (51) is a natural, nonnitrogenous neoclerodane diterpene isolated 
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from Salvia divinorum which has been found to be highly selective, potent  agonist [241]. 
Nalfurafine (52), which is used to treat uremic pruritus, is another selective  agonist [242].  
Figure 13. Other example of receptor ligands
 
1.7 Endogenous Opioid Peptides 
Both the adverse and helpful effects of opioid drugs come from their interaction with the 
endogenous opioid systems. Opioid receptors and endogenous opioid compounds are present 
throughout the body, and are concentrated in the peripheral and central nervous systems [144].  
25 
 
Among the opioid peptides produced by the body are the endorphins, enkephalins, 
dynorphins, and endomorphins. Each type of endogenous opioid peptide comes from a different 
precursor protein and has its own distinct anatomical distribution. These precursor proteins, 
poreproenkephalin, preprodynorphin, and preproopiomelanocortin are encoded by their 
corresponding genes and are responsible for the enkephalins, dynorphins, and endorphins, 
respectively [145]. Modifications after translation produce multiple active opioid peptides. 
Although endorphin is the primary opioid peptide encoded by preproopiomelanocortin, it is also 
the precursor for several non-opioid peptides, including adrenocorticotropic hormone (ACTH), -
melanocyte-stimulating hormone (-MSH) and -lipotropic pituitary hormone (-LPH) [146]. 
Preproenkephalin encodes a multiple met-enkephalins and a single leu-enkephalin. These include 
a heptapeptide and octapeptide met-enkephalin [147]. Predynorphin produces three peptides of 
different lengths, dynorphin A, dynorphin B, and neoendorphin, all of which begin with the same 
sequence as enkephalins [148]. These peptides have the amino-terminal sequence known as the 
“opioid motif” which consists of Tyr-Gly-Gly-Phe-(Met or Leu) [149]. After this sequence come 
different C-terminal extensions resulting in peptides ranging from 5 to 31 residues [149-151].  
1.7.1 Endorphins 
The endorphins are endogenous opioid polypeptide compounds produced by the pituitary 
gland and hypothalamus. They are released during a variety of activities, including strenuous 
exercise [152], excitement, orgasm, and pain. Endorphins are known as “natural pain relievers” 
because they are similar to opiates in their analgesic properties and ability to give a feeling of 
well-being. They occur naturally in a number of different parts of the body, including the 
pituitary gland, brain, and central and peripheral nervous systems [153,154]. There are four types 
of endorphins produced by the human body, called alpha, beta, gamma, and sigma endorphins; 
they each have a different number, ranging from 16 to 31, of amino acids in their molecules 
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[155]. Beta-enkephalins are type of Met-enkephalin, which are plentiful in the hypothalamus and 
the pituitary gland. Endorphins are released by the body in response to stress or pain. In case of 
pain, endorphins produce an analgesic effect, which lessens the pain the experienced by the 
body. During stress, endorphins act on the limbic system to reduce anxiety. The endogenous 
opioids not only can reduce pain and stress, but also can produce feelings of euphoria and trigger 
the release of sex hormones [156]. Beta-endorphins: sequence: "Tyr Gly Gly Phe Met Thr Ser 
Glu Lys Ser Gln Thr Pro Leu Val Thr Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala Tyr Lys Lys Gly 
Glu” [157]. 
The properties of endorphins result from their action on the opioid receptors. Beta 
endorphins have high affinity for the 1 receptor, lower affinity for the  and 2 receptors, and 
very low affinity for the  receptor. The  receptors are “presynaptic” and also prevent the 
release of GABA, an inhibitory neurotransmitter, decreasing the inhibition of dopamine 
pathways. This causes more dopamine to be released. Exogenous opioids take advantage of this 
and trigger excessive dopamine release, causing aberrant synaptic plasticity, which then leads to 
addiction. Endorphins play other roles in the body’s systems as well. They are also believed to be 
involved in preventing diabetes, obesity and psychiatric diseases [155]. Athletes’ bodies produce 
high levels of endorphins during strenuous exercise, leading to a “runner’s high,” which has 
become a general term for the feeling of power and near-invincibility that can result from high 
levels of endorphins. [155] 
1.7.2 Enkephalins:  
All enkephalins are pentapeptides. They are responsible for regulating nociception in the 
body. There are two different types of enkephalins, Leu-enkephalins, which contain leucine, and 
Met-enkephalins, which have methionine. Both types of enkephalins are encoded by the 
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proenkephalin gene [158]. Met-enkephalins occur in the brains of humans and other animals, and 
are an endogenous opioid peptide neurotransmitter. Leu-enkephalins have selectivity for the µ 
and δ opioid receptors, though they show much higher selectivity for δ. Met-enkephalins have 
Tyr-Gly-Gly-Phe-Met. Leu-enkephalins have Tyr-Gly-Gly-Phe-Leu [163].  
1.7.3 Dynorphins 
 Dynorphins are encoded by prodynorphin, which is cleaved by proprotein convertase 2 
(PC2), producing dynorphin A and dynorphin B [161, 162]. Dynorphin A and Dynorphin B 
contain lysine, arginine, and hydrophobic residues. Dynorphins occur in many different parts of 
the brain and have a number of physiological effects depending on where they are located. For 
instance, dynorphins found in the magnocellular vasopressin neurons of the supraoptic nucleus 
serve to regulate electrical activity in the brain, while the dynorphins produced in orexin neurons 
in the lateral hypothalamus and in the arcuate nucleus help to regulate appetite [162]. 
Dynorphins are stored in dense-core vesicles much larger than vesicles for neurotransmitters, 
which take a much longer and more intense stimulus for them to be released into the synaptic 
cleft. Dense-core vesicle storage is characteristic of opioid peptide storage [159]. 
The effects of Dynorphins come from their interactions with the k-receptor. Dynorphins 
modulate pain response and have effects on various body systems, including appetite and weight 
control, circadian rhythm, and body temperature. 
1.7.4 Endomorphins  
Endomorphins are of two types of tetrapeptides-Endomorphin-1 (Tyr-Pro-Trp-Phe-NH) 
and Endomorphin-2 (Tyr-Pro-Phe-Phe-NH) [164].  
    There are two types of endomorphins, Endomorphin-1 and Endomorphin-2, both of 
which have a high affinity for the µ receptor. The distribution of Endomorphin-1 is concentrated 
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in the brain and upper brainstem, specifically in the nucleus accumbens, cortex, amygdala, 
thalamus, hypothalamus, the striatum, the dorsal root ganglia, the nucleus of the solitary tract, 
the periventricular hypothalamus and the dorsomedial hypothalamus. In the dorsomedial 
hypothalamus, Endomorphin-1 occurs in the histaminergic neurons, where it is thought to help 
regulate sedative and arousal behaviors. Endomorphin-2 is found in the lower brainstem and the 
spinal cord. Endomorphins help regulate the body’s response to stress and perception of pain, in 
addition to a number of complex neurological functions such as arousal, reward, and vigilance, 
and are partly responsible for regulating cognitive, autonomic, neuroendocrine and limbic 
homeostasis. [160]. 
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I.2 AIM AND APPROACH 
2.1 Structural information of opioid receptors (μ, δ and к) 
Opioid drugs target the four types of opioid receptors, the µ, δ, к, and nociception 
receptors. Each type of receptor plays its own pharmacological role and has its own function, 
even though there is a high degree of similarity among the receptors [171]. Up until recently, 
successful receptor-based drug design was extremely difficult, because the interaction between 
opioid drugs and the receptors was not understood on a molecular level. However, since the 
reporting of the crystal structures of the opioid receptors [172-175], researchers have been able 
to take advantage of this knowledge to discover new compounds which target these receptors and 
may be useful for pharmacological and medical purposes. Each receptor crystallizes around a 
high-affinity ligand. Studies have shown the µ receptor crystallized around β-funaltrexamine 
(53), an irreversible morphinan [176] (Figure 14). The crystalline structure of the δ receptor has 
been observed with naltrindole (54) [177], and that of the nociception receptor with the peptide-
mimetic compound 24 (55) [178] while the crystalline structure of the к receptor was shown in 
the presence of JDTic (24) [179].  
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Figure 14. Ligand crystalized with opioid receptor
 
Figure 15 shows an overlap of the three opioid receptors, which are typical of GPCR 
having seven pass TM helix folds. As mentioned in the introduction, these receptors are 
connected by three intracellular and three extracellular loops (ILs and ELs, respectively). The 
sequence identity of the opioid receptors within the TM domains is 76% between μ and δ, 73% 
between μ and κ, and 74% between δ and κ, showing that these receptors share a similar 
structural fold, even in the less conserved loop regions [240]. This makes it extremely 
challenging to design ligands selective a particular receptor. The pockets in the opioid receptors 
where ligand binding occurs are solvent-exposed and have similar shapes. Figure 16 shows the 
interaction modes of β-funaltrexamine (left panel) and naltrindole (right panel), in the MOR and 
DOR receptor crystal structures, respectively. Figure 16 shows the binding mode of µ and δ 
receptors with morphinan ligands β-funaltrexamine and naltrindole, respectively, where the 
similar ligands occupy a similar area delimited by helices TM3, TM5, TM6, and TM7 in the 
binding pockets. A direct comparison between the δ and µ receptors shows that 11 of the 14 
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amino acids in the pocket area around the ligands are identical.  The three differences are at μ 
positions E229, K303, and W318, which are Asp 210, Trp 284, and Leu 300 in the δ, 
respectively. The leucine in position 300 in the μ receptor interacts with the indole group of 
naltrindole. The result is that naltrindole is selective for δ, because neither the W3187.35 in μ nor 
the Y312
7.35
 in κ are sterically compatible with naltrindole binding [173]. 
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Figure 16. 
Binding mode of β-funaltrexamine (left panel), naltrindole (right panel), in the MOP and DOP receptor 
crystal structures, respectively
 
A “message-address” analogy has long been used to describe opioid pharmacology, 
where each ligand is seen as having two distinct parts [243]. The “message” is the part that 
determines efficacy, while the “address” determines selectivity. This pharmacological 
phenomenon is a direct result of the structure of the opioid receptors, as studies of the structure 
of the δ and other receptors have shown. Because the lower region of the binding pocket is very 
similar in all three receptors, this section recognizes the core morphinan group, and receives the 
“message” part of the ligand (Figure 17). The upper region of the receptor binding pocket has 
more differences between the receptors, and is mostly responsible for determining selectivity. 
The part of the ligand which interacts with this upper region of the receptor is called the 
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“address.” Applying these concepts to naltrindole explains its selectivity for δ through the indole 
“address”.  
Figure 17. The different amino acid between μ and δ receptor 
 
Applying the “message-address” concept to the analysis of the binding mode of JDTic in 
the κ receptor (figure 18) explains the selectivity of it and similarly shaped ligands for the μ and 
κ receptors. The “message” part of the ligand is tetrahydroisoquinoline which interacts with the 
same area of 3-hydroxy group of morphinans of the receptor. The 3-hydroxyphenyl group 
“address” of JDTic interacts unfavorably with amino acid K1082.63 in the upper region of the δ 
receptor, making JDTic selective for the κ and μ receptors.
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We have chosen to focus on the µ receptor because of its important role in opioid 
dependence. It is well known that the major side effects of opioid analgesics results from 
activation of the µ receptors [69]. The most serious side effect of these drugs is respiratory 
depression, which is the most common cause of death in the case of overdose (see section 1.6). 
Morphine and similar opioid drugs bind with all three opioid receptors to produce analgesic 
activity. Selective antagonist for the μ receptor such as GSK151498 (56) (Figure 14) shows 
reduced compulsive consumption of abusive substances, such as heroin and cocaine.in rodent 
models [133]  
In this study we aim to design a new ligand that bind selectively to the μ receptor. To 
eliminate the receptor most similar to μ, which is δ, from binding with the new target ligand, a 
pharmacophore has been designed based on the crystalline structure of JDTic inside the к 
receptor. Our target ligand needs to have a similar shape and electrostatic of JDTic as well as 
bind in the same mode as JDTic to prove the hypothesis that the K108
2.63
 amino acid in the δ 
receptor is part of the “address” concept. A library of 19 million compounds was the subject to a 
combination docking method that integrates ligand and receptor centric virtual screening search 
techniques in order to screen libraries of commercial compounds. 
2.2. Ligand and receptor based virtual screening 
2.2.1 Compound Library 
In this study all purchasable molecules in the ZINC database were downloaded. A total of 
19,607,982 compounds in the SD format were downloaded as of December 2013 [187]. 
Compounds containing any atoms other than H, C, N, O, F, S, Cl, and Br and improper 
functional groups were first removed using FILTER v2.0.2 [188]. These compounds were 
filtered to satisfy Lipinski’s rules with a maximum violation of two of the rules and additional 
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criteria, such as Mwt 200-600, number of heavy atoms 15-35, number of ring systems 0-5, ring 
size 0-20, number of connected non-ring atoms 0-15, number of functional group 0-18, number 
of connected unbranched non-ring atoms 0-6, number of carbons 7-35, number of heteroatoms 2-
20, heteroatom to carbon ratio 0.10-1.0 and halide fraction 0.0 minimum to 0.5 maximum. We 
used the second ring degree of freedom option to eliminate compounds based on the number of 
rotatable and rigid bonds, hydrogen bond donor and acceptor, number of oxygen and nitrogen 
atoms, formal charges, XlogP and solubility. Other functional group rules were included to 
eliminate quinone, triflates, phosphoryl compounds, cations, alkylphosphate, nitroso derivatives, 
Michael acceptors and other undesirable functional groups. 
In order to conver the compounds to 3D multiconformer structures and add hydrogen 
atoms/Gasteiger partial charges, we used OMEGA v.2.1 (http://www.eyesopen.com). The first 
docking step required rigid body shape-fitting multiconformer structures (see section 2.3), which 
were created with OMEGA using an algorithm which disassembles molecules into component 
fragments, then reassembles them in a variety of possible combinations. OMEGA then submits 
the new conformers to a simplified energy evaluation (modified Dreiding forcefield, 
http://www.eyesopen.com) and compares those below a certain energy threshold. The 
conformers within a certain RMS distance are clustered into a single representation. We changed 
the parameters associated with root mean squared deviation RMSD value in order to achieve the 
optimal compromise between speed, structural diversity and number of conformers generated. 
For these purpose RMSD was set to 0.5 Å, the energy window (used to dismiss high energy 
conformations) was set to 10.00 kcal/mol, and the number of conformers generated per 
compound was set to 300. These parameters are used in order to allow fast rigid-body filtering, 
although they do not reproduce exactly the docking conformation and pose. In addition, in order 
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to increase the variability of the conformers generated, we set a large energy window, which was 
necessary because the conformation of small molecules, when cocrystallized into an active site, 
can at times differ greatly from global minimum energy conformations. 
2.2.2 Ligand-Based Screening of data base  
In a single conformation query approach we also utilized the bound conformation of the 
JDTic к antagonist from the available high resolution crystal structures of к receptor. The ligand 
conformations from the crystal structures of the JDTic complexes in the inactive (pdb id 4DJH 
obtained from the RCSB Protein Data Bank (PDB) [189]) was selected as representative query 
for ligand-centric virtual screening. The ligand was extracted from the protein crystal structure 
by the software, “make receptor” of OpenEye [190]. Query was created based on extracted 
ligand by using the application “vROCS” from OpenEye software [190]. The two test sets of 
compounds, the first consisting of 35 compounds from the IUPHAR/BPS Guide to 
PHARMACOLOGY, including ligands known to have binding activity for opioid receptors 
[191], and the decoy set, which included compounds that have no known activity on the protein 
targets, were prepared from the IUPHAR/BPS Guide to PHARMACOLOGY [191]. Both test 
sets were used to validate query using vROCS [192]. The AUC of query was found to be 0.99. A 
well-established and robust ligand screening platform, ROCS (rapid overlay of chemical 
structures) [193-195], was used for shape-based virtual screening of the data sets. This model 
employs a physically rigorous measure of 3D similarity to the ligand queries, which is combined 
with a simple force field that measures matching of the appropriate chemical functionality of 
ligand−protein interactions. The scoring functions included in ROCS are based on two distinct 
aspects: shape similarity (“ShapeTanimoto”) and chemical pattern (“ColorScore”) similarity. The 
basic scoring function implemented in ROCS is the ShapeTanimoto score, which is a 
quantitative measure for the shape overlap of two molecules. ColorScore is the scoring function 
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that quantifies the matching of these chemical functionalities between the query compound and 
the molecule being screened. We used “ComboScore”, which is a combination of 
ShapeTanimoto and ColorScore [193-195]. Pairwise 3D shape similarities of the generated 
conformers against the crystal ligands were quantitatively calculated using the ROCS program 
(version 2.2) [192]. As a result of shape-based filteration of curated ZINC database, 70,000 
possible hits generated.  
2.2.3 Protein-based Screening of data set 
FRED (Fast rigid exhaustive docking, OE Scientific) is a protein–ligand docking 
program, which docks and scores molecules in a multiconformer database against the receptor 
structure of a biological target. FRED 2.1.2 [196]. The receptor binding site was created for all 
four receptors involve in this study, which were download from PDB (4DKL for the MOR, 4EJ4 
for the DOR, 4DJH for the KOR, and 4EEA3 for NOR.), were generated using “make receptor” 
software (OpenEye) [197]. All receptors used in this study were co-crystallized with ligands. The 
bound ligands were used to specify the active site. A 3D box was generated around each ligand 
to enclose the active site. No constraints were added during the grid generation.  
Ligand conformational sampling was used with the FRED and HYBRID modules of 
OpenEye. We used OMEGA (OpenEye) as the conformer generator. First we docked the ligand 
conformational sample with FRED in order to eliminate any compound that has a low docking 
score in the µ receptor. The output of the docking was processed by OMEGA in order to 
regenerate conformers, so that HYBRID can be used to redock the newly generated conformers 
with all opioid receptors to eliminate any compound not selective for µ receptor only. 
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I.3 RESULT AND DISCUSSION 
We screened in silico over 19 million lead-like compounds from the database using a 
combination docking method that integrates ligand and receptor centric virtual screening 
techniques. The 700 top scoring docking hits were clustered based on the skeleton diversity. The 
compounds in each cluster were prioritized based on docking score. Specific compounds were 
visually inspected and chosen based on docking score, chemotype diversity, the presence of 
polar interactions between the ligand and the Asp147 residue in µ , unique binding modes 
different from classical alkaloids, and purchasability. 
As a result, seven compounds were chosen, one from each cluster, which fit the criteria 
we were looking for. The compound 14984263 (compound 1) showed binding to both the µ and 
к receptors which is representative of the successful outcome of virtual high throughput 
screening (HTS) (section 2.1) 
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Figure 19. The 7 compounds chosen based on the criteria. 
 
Figure 20. Compound 1 and general structure of indole-2-carboxamides 
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Compound (1) produced a concentration-dependent inhibition of specific [3H]-U69,593 
(κ) binding with a Ki value of 445 μM (Figure 21). Compound (1) also inhibited specific [3H]-
DAMGO (μ) with Ki values 44 nM (Figure 21), while no binding affinity toward δ opioid 
receptors was observed. To characterize the relative efficacy and potency of compound (1), it 
was assayed in a [35S]GTPγS functional assays (Figure 22). 
Figure 21.  
Inhibition constants (Ki) obtained for Compound (1) and control opioid antagonist ligand naloxone 
hydrochloride at κ and μ opioid receptors. 
 
Compound 1 was tested for its ability to stimulate [35S] GTPγS binding mediated by the 
κ and µ opioid receptors. Compound (1) showed no activation of the G protein (i.e., was an 
antagonist) for both κ and µ receptors in a GTPγS assay compared to full agonists U69,593 (к) 
and DAMGO (μ) (Figure 22).  
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Figure 22.  
GTPγ35S agonist functional assay tests whether test compound (1) can activate G-protein. 
 
 
Antagonism was confirmed by running GTPγS assays with a fixed amount of agonist 
against a dilution series of compound (1) and known opioid antagonist naloxone hydrochloride 
(Figure 23). Both compound (1) and naloxone were able to antagonize 20 nM U69,593 (к) or 
200 nM DAMGO (μ) agonist activity, with IC50 values of 511.2+/-175.3 nM and 3.229+/-0.942 
nM, respectively, for к, and 774.9+/-107.3 nM and 11.78+/-1.70 nM, respectively, for .  
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Figure 23. 
 Fixed agonist assay tests whether test antagonist compound (1) can antagonize ~EC80 concentration of 
agonist. 
 
 
 
Additionally, apparent  and  competitive antagonism was indicated by assaying 9 M 
or 0.9 M of compound (1), respectively, against a dilution series of agonists U69,593 () or 
DAMGO (); compound (1) right-shifted the curves compared to vehicle but did not alter the 
assays Emax (Figure 24). 
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Figure 24.  
Fixed antagonist assay test whether test antagonist compound (1) can right-shift agonist dose-response 
curve 
 
 
 
 
To explain the biological activity of compound 1, a computational study was carried out 
in parallel to investigate the reason behind the biological data. The X-ray structures of the opioid 
receptors have been published in the past few years [172-175]. Each receptor crystallizes around 
a high-affinity ligand. These structures correspond to Protein Data Bank (PDB) identification 
codes 4DKL for the μ receptor, 4EJ4 for the δ receptor, 4DJH for the к receptor, and 4EA3 for 
46 
 
the NOP receptor [172-175]. Molecular docking of compound 1 into the к crystal structure 4DJH 
(к receptor was shown in the presence of JDTic [179]) were carried out using FRED 2.1.2 [196] 
and compared to the docked pose of JDTic in the к crystal structure. Like JDTic’s V-shaped 
bound orientation in the к crystal structure, compound 1 binds to к receptor with a V-shaped 
orientation. The pyrrolidine nitrogen makes the classic ionic interaction with the conserved Asp 
138 of TM3. The presence of the conserved Asp 138 in aminergic GPCRs is necessary to 
identify protonated-amine-containing ligands and is responsible for the binding of the receptors 
to those ligands. Asp138 is conserved in all opioid receptors and mutagenesis studies show that 
this amino acid is essential to anchor positively-charged ligand (figure 25a) [198]. Compound 1 
showed high similarity in binding to JDTic, where both fit tightly to the bottom of the binding 
cleft (Figure. 25b), forming ionic, polar, and extensive hydrophobic interactions with the 
receptor. 
 JDTic interacts with four amino acids that are not found in other opioid receptors [199] 
(Figure. 26), which contributes to JDTic’s selectivity for the к receptor and is present in other к 
selective ligands as well. These four amino acids are as follows (the amino acids found in μ and 
δ receptors, respectively, are in parentheses): Val1082.53 (Ala and Ala), Val1182.63 (Asn and Lys), 
Ile294
6.55
 (Val and Val), and Tyr312
7.35
 (Trp and Leu). 
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Figure 26. 
 Diagram of JDTic (gray) interactions in the binding pocket side chains. Residues that vary among μ, δ 
and к subtypes are highlighted in red. 
 
Analysis of the amino acids involved in the binding of JDTic to the к receptor show that 
the all described residues can contribute to the JDTic selectivity profile [200-202]. In the к 
receptor, Val118
2.63
 is important to the selective binding of JDTic in the receptor. When it is 
replaced with Lys
2.63
 (found in the δ receptor) these larger hydrophilic amino acids interfere with 
the interaction between the ligand and receptor resulting in unfavorable contact with the JDTic, 
making JDTic selective for к only. In contrast, with compound 1, replacing Val118 with Asn2.63 
found in the μ receptor does not result in unfavorable interaction between the compound 1 and 
the receptor, allowing compound 1 to bind to both the к and μ receptors. Because compound 1 
occupies less space than JDTic (figure 25b) compound 1 forms extra interaction with μ receptor 
through Asn
2.63
 than it has with the Val118 in к (Figure 27), which explains why compound 1 is 
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slightly selective for μ. Replacing the Val1182.63 with the even larger Lys2.63 found in δ creates 
unfavorable interaction for both JDTic and compound 1, which makes compound 1 bind with к 
and μ only. 
Figure 27. Shows the extra interaction of compound 1 with Asn2.63 found in μ. 
 
A series of closely related derivatives of compound (1) was first tested to obtain an SAR 
that could serve as a starting point for further structural optimization (Table 2, compounds 1−26). 
Replacing the 3-phenolic hydroxy group on the benzyl ring of compound 1 with either a 
chloride, trifluoromethyl or phenoxy (5, 6, and 8, respectively) completely abolished к binding 
affinity, while only compound 5 showed low Ki for μ receptor. In the к receptor, the 3-phenolic 
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hydroxy group of compound 1 forms a polar interaction, mediated by a water molecule, with 
amino acids C210 and W124 (figure 28) , just as JDTic does, as shown by Stevens, et. al. [175]. 
Figure 28. 
Shows the polar interaction of compound 1 mediated by a water molecule, with amino acids C210 and 
W124. 
 
In the μ receptor, the 3-phenolic hydroxy group either forms this same type of interaction 
with amino acid C217 and W133 or forms a direct polar interaction with Asn
2.63
, which is not 
found in other similar opioid receptors. Replacing the 3-phenolic hydroxy group with the 
chloride or trifluoromethyl, in either к or μ interferes with these polar interactions, reducing or 
eliminating the binding affinity for these receptors. When the 3-phenolic hydroxyl group is 
replaced with a phenoxy the large size of the phenoxy interferes with the interaction between the 
compound and the receptor; 3,5-dimethoxy substitutions on the benzyl ring (7) have the same 
result. 
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Para hydroxyl substituted compound showed 6.8 more selectivity for μ than к (Table 2), 
but did not significantly improve the affinity. This is because moving the hydroxyl group from 
position 3 to position 4 in the phenol ring may results in the interrupt of interaction between the 
hydroxyl group and the amino acids C210 and W124 in the к receptor (figure 29). 
Figure 29 A. 
 Shows compound 1 (turquoise) with 3 and para hydroxyl and amino acids C210 and W124 in the к 
receptor. 
 
In μ, moving the hydroxyl group to position 4 gets it closer to the Asn2.63, allowing it to 
form a polar interaction leading to selectivity for the μ receptor (figure.30). Replacing the 3-
hydroxyl group with hydrogen led to the elimination of к binding affinity and a decrease in μ 
binding affinity, due to the loss of the polar interaction between the hydroxyl group and the 
amino acids in both receptors and the interaction between hydroxyl and Asn
2.63
 in the μ receptor. 
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In agreement with observations for compounds 1-8, para and meta hydroxyl groups on the 
benzyl ring gave the best binding affinity compared to other substitutions. 
Figure 29 B.  
Shows compound 1 (turquoise) with para hydroxyl group for polar interaction with Asn
2.63
 
 
Modification of pyrrolidin-3-ylmethanamine (1-8) to pyrrolidin-3-amine (9) showed 
significant enhancement in binding affinity for all three opioid receptors with weak selectivity 
because the modification decreased the size of the space occupied by these ligands, preventing 
the unfavorable interaction found between compound 1 and the δ receptor. As before, replacing 
the hydroxyl of compound 9 with chloride or trifluoromethyl led to completely abolished к 
binding affinity while only compound 12 showed a low Ki for the μ receptor; replacing the 
hydroxyl of compound 9 with hydrogen enhances the selectivity for both μ and к. Compounds 
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13-26 showed the modification done on indole ring. As shown in Table 2, adding substitutions 
reduced the binding affinity and improved the selectivity.  
Table 2.  
Binding Affinity of a Series of indole-2-carboxamide at the opioid receptors μ, к and δ. 
 
     
compound X Y R δ К μ  
1 H 3-OH H  284.723.4  144.211.9 
2 H 4-OH H ND 1712360 250.69.4 
3 H 2-Cl H ND 1756195 899.565.0 
4 H H H ND 1484219 1408100 
5 H 3-Cl H ND ND 3442338 
6 H 3-CF3 H ND ND ND 
7 H 3,5-OCH3 H ND 48721218 551.079.9 
8 H 3-phenoxy H ND ND ND 
9 H 3-OH H  41.245.42 49.333.02 
10 H 3-CF3 H ND ND ND 
11 H H H ND 429 278 
12 H 3-Cl H ND 4486 ND 
13 5,7-CH3 H CH3 ND 2372268 ND 
14 6-CH2CH3 H H ND 3874436 ND 
15 4-CH3 H H ND 1056190 812. 100 
16 5,7-CH3 H H ND 1853155 ND 
17 4,6-CH3 H H ND 4699944 ND 
18 7-Cl H H ND 484.058.1 1917273 
19 5-OH H H ND ND ND 
20 6-(CH3)N H H ND ND ND 
21 5,7-CH3 H H ND 654.656.4 ND 
22 6-CH3 H H ND ND ND 
23 5,7-Cl H H ND 4061629 ND 
24 4,6-CH3 H H ND 518.769.6 ND 
25 4-CH3 H H  112.710.7 914.751.7 
26 5,7-CH3 H CH3 ND 3716896 ND 
ND: ligand shows > 70% inhibition     
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Only compounds 1, 2, 9, 11 and 25 have Ki less than the cutoff (cutoff = 400nm); these 
compounds were then subject to an investigation of their ability to stimulate [35S] GTPγS 
binding mediated by the κ and µ opioid receptors. Compounds 1, 2 and 9 showed no intrinsic 
(agonist) activity, meaning they were unable to activate the G protein (i.e., were antagonists) for 
both κ and µ receptors in a GTPγS assay compared to full agonists U69,593 (к) and DAMGO (μ) 
(Figure 30-32). Compounds 11 and 25 showed partial agonist activity (Figure 33), while 
compounds 1, 2, and 9 had potent binding affinity at all three opioid receptors and no intrinsic 
activity, their antagonist potency and nature of antagonism was determined from the inhibitions 
of agonist-stimulated [35S] GTPγS binding curves in the presence of dilutions series of the target 
compounds and known opioid antagonist naloxone hydrochloride. At μ and κ, Compound (1) 
caused a significant rightward shift of the concentration-response curve of DAMGO and 
U69,593, respectively (Figure 34). The antagonist potency, calculated as the Ke value, was 
644.19 nM and 27.65 nM for κ and μ, respectively. Note that Ke value for potency at κ and μ 
shows a preference 23 times greater for μ than for κ. Compound 2 and 9 were also subject to 
fixed agonist and antagonist functional assays. Both compounds show the same pattern as 
compound 1, where compound 2 was able to antagonize 25 nM DAMGO (μ) agonist activity, 
with IC50 values 6.64 µM (Figure 35A). Compound 9 antagonizes all three opioid receptors with 
IC50 3.71 µM for δ, 130.6 nM for κ, and 103 nM for μ (Figure 35B-D). The antagonist potency 
of compound 2 was found to be 57.77 nM for μ (Figure 36). Compound 9 shows a significant 
preferential antagonist potency for μ with Ke value 17.63 nM, while the Ke value for κ and δ 
were 72.18 nM and 219.17 nM, respectively (Figure 36). 
.
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3.1 Tri amide substitution of Carboxamide 
Compound 1 was the subject of more investigation, in which we replaced the indole ring 
and added substitutions at the amide nitrogen, as can be seen in figure 37 (compounds 27-39).  
Figure 37. Structure of Compounds 27-39 
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Replacing the indole ring with a furan ring eliminated the activity in both the μ and κ 
receptors (27), whereas replacing the indole ring in pyrrolidin-3-amine derivatives of compound 
1 makes it selective for κ only with reduced affinity (28). Further modification by replacing 
indole-2-carboxamide with aniline led to the abolishment of all activity in the opioid receptors 
(29), while replacing it with methylpyridin-2-amine increased the selectivity for κ and decreased 
the affinity (30). As mentioned in section 2.1 JDTic and compound 1 have the same V-shaped 
orientation in the κ receptor (figure 25B); however, the isopropyl group in the JDTic occupies a 
deep pocket in the receptor which compound 1 has no group to occupy (figure 38). 
Figure 38. Isopropyl group in the JDTic occupies a deep pocket
 
The next step was to modify the compound 1 by performing tertiary substitution on the 
nitrogen of the amide group, with the hope that the new addition would occupy this pocket. 
Compound 31 was the first compound we produced with this modification, created by adding a 
phenyl group to the nitrogen of the amide group but it showed no binding to any of the three 
opioid receptors. This may be explained by the size of the compound. We replaced the indole-2-
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carboxamide ring of compound 31 with furan, creating compound 32, which showed high 
binding affinity for μ with five times the selectivity for μ than κ, and 76 times the selectivity for 
μ than for δ. Next we further modified compound 32 by replaced furan-2-carboxamide with 
propionamide, forming compound 33, which showed high binding affinity for and much better 
selectivity for μ, with 13 times the selectivity for μ than for κ and no binding for δ. The previous 
finding from the earlier series shows that the 3-hydroxy and 4-hydroxy group of the phenyl ring 
are significant for the binding affinity, motivating us to modify compound 32 by adding a 
hydroxyl group at positions 3 and 4 of the benzyl group to form compounds 34 and 35, 
respectively. These modifications showed no improvement in the affinity and led to reduced 
selectivity. In order to eliminate the binding of compound 32 for the δ receptor, we increased the 
length of the compound 32, to take advantage of the selective amino acid in the upper part of the 
opioid receptors such as Lys 108 which were discussed in the previous section. Increasing the 
linker on the pyrrolidine nitrogen as in Compound 36 (figure 37) improved binding affinity and 
preference for µ over κ when compared to 32 (table 3). In compound 37, increasing the linker 
between the phenyl and the amide nitrogen eliminated binding affinity for δ and increase 
preference for к over µ by approximately three fold. Increasing the linker on the amide nitrogen 
and the pyrrolidine nitrogen, as in compound 38, showed selectivity for к but with a lower 
affinity.  
 Molecular docking of compound 32 into the к crystal structure 4DJH (к receptor was 
shown in the presence of JDTic [179]) was carried out using FRED 2.1.2 [196] and compared to 
the docked pose of JDTic in the к crystal structure. The pyrrolidine nitrogen makes the classic 
ionic interaction with the conserved Asp 138 of TM3. Compound 32 showed high similarity in 
binding to JDTic, where the furan-2-carboxamide occupied the deep pocket that is occupied by 
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the isopropyl of JDTic (Figure. 39), and the benzylpyrrolidine moiety takes the same place of 
isoquinoline of JDTic, forming ionic, polar, and extensive hydrophobic interactions with the 
receptor, and the phenyl group of both compounds extends to form a hydrophobic interaction 
with TM2 
Table 3: Binding Affinity of a compounds 27-39 at the opioid receptors μ, к and δ. 
 Inhibition 
% 
  Ki (nM) 
compound δ к Μ δ К μ  
27 41.8 51.0 38.3 ND ND ND 
28 27.2 81.8 41.1 ND 498.462.7 ND 
29 40.1 68.1 52.9 ND ND ND 
30 47.1 85.7 64.4 ND 1338171 ND 
31 60.8 57.6 27.9 ND ND ND 
32 79.1 96.3 99.5 2294318 149.4  27.3 29.91  3.20 
33 54.7 90.7 98.2 ND 1010166 ND 
34 94.9 98.3 99.5 302.524.4 742.834.5 57.653.39 
35 86.3 93.6 96.4 814.859.2 147.416.5 35.981.68 
36 86.4 95.8 100 1019  111 411.231.4 140.311.7 
37 73.1 92.4 86.5 ND 162.4  21.5 18.50  1.72 
38 48.4 85.7 78.7 ND 94.8410.31 324.241.6 
39 - 39.3 34.9 ND 572.6  65.7 ND 
ND: ligand shows > 70% inhibition 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
 
 
 
Figure 39. Compound 32 (yellow) and JDTic (magenta) in κ.  
 
 
Pyrrolidine nitrogen and tertiary amide nitrogen interact with the conserved Asp 138, 
similar to the interaction found between Asp 138 and both piperidine nitrogen and isoquinoline 
Tic-nitrogen  in JDTic. These bidentate interactions may be the reason behind the strong binding 
of 32. As shown in Figure 39 and in agreement with the rule of Lys 108 in δ, compound 32 
showed moderate binding to δ. Unlike its orientation in the κ, 32 binds to μ in the opposite 
66 
 
orientation (Figure 40) with the pyrrolidine nitrogen and tertiary amide forming the same 
interactions with Asp 147, and the phenyl ring buried down in the deep pocket of the μ receptor.  
Figure 40. Shows the binding mode of 32 in μ.  
 
Compound 33 was formed by replacing the furan ring with an ethyl group. In both µ and 
κ, 33 shows an orientation with the phenyl group buried down in the deep pocket of the receptor, 
similar to 32 (Figure 41).
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Compounds 34, and 35 shown moderate binding to δ. Based on the effect of the selective 
amino acid Lys 108 found in the upper part of the opioid receptors, which was discussed in the 
previous section, compound 32 was modified in order to eliminate the binding to δ. Increasing 
the length of compound 32 eliminated δ receptor binding to the new analogs 36 37 and 38. 
Compound 38 binds only to κ; this result proves the efficiency of using Lys 108 as an address in 
order to design a selective ligand for κ and µ (Figure 42-43).  
Compound 37 showed high binding similarity to JDTic, where the furan-2-carboxamide 
occupied the deep pocket that is occupied by the isopropyl of JDTic. (Figure.42), and the 
benzylpyrrolidine moiety takes the same place of isoquinoline of JDTic, forming ionic, polar, 
and extensive hydrophobic interactions with the receptor, and the phenyl group of both 
compounds extends to form a hydrophobic interaction with TM2. Compound 37 showed higher 
similarity to JDTic than other compounds (Figure 42); this explain the binding data, where 37 
showed more preference toward κ than µ. Unlike its orientation in the κ, 37 binds to μ in the 
opposite orientation (Figure 45) with the pyrrolidine nitrogen and tertiary amide forming the 
same interactions with Asp 147, and the phenyl ring buried down in the deep pocket of the μ 
receptor. Increasing the length more such as in 38, makes it bind only to κ.
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Compounds 32, 33, 34, 35, 36 and 37 produced a concentration-dependent inhibition of 
specific [3H]-U69,593 (κ) binding with a Ki value of 149.4.027.3, 742.834.5, 147.416.5, 
411.231.4, 162.4 and 94.84 nM, respectivily (Table 3). These compounds also inhibited 
specific [3H]-DAMGO (μ) with Ki values 29.913.2, 57.653.39, 35.981.68, 140.311.7, 
18.501.72 and 32441.6 nM, respectively ( Table 3), while moderate binding affinity toward δ 
opioid receptors was observed for 32, 34, 35, and 36. The same cutoff used for the previous 
series (cutoff = 400nm), was used for these compounds. Only compounds 32, 33, 34, 36 and 37 
have Ki less than the cutoff; these compounds were then subject to an investigation of their 
ability to stimulate [35S] GTPγS binding mediated by the κ and µ opioid receptors. Compound 
32 showed no intrinsic (agonist) activity, meaning it was unable to activate the G protein (i.e., 
was an antagonist) for µ receptors in a GTPγS assay compared to full agonists U69,593 (к) 
(Figure 44). Compound 33 showed partial agonist activity (Figure 45), while compound 32 had 
potent binding affinity at all three opioid receptors and no intrinsic activity at (µ); its antagonist 
potency and nature of antagonism was determined from the inhibitions of agonist-stimulated 
[35S] GTPγS binding curves in the presence of dilutions series of the target compounds and 
known opioid antagonist naloxone hydrochloride (since compounds 34 and 35 are close analogs 
to 32, their antagonist behavior was confirmed through fixed agonist and antagonist assays). At μ 
and κ, Compound (32) caused a significant rightward shift of the concentration-response curve of 
DAMGO and U69,593, respectively (Figure 46). The antagonist potency, calculated as the Ke 
value, was 117.6 nM and 58.8 nM for κ and μ, respectively. Compound 34, 35, 36 and 37 were 
also subject to fixed agonist and antagonist functional assays. All four compounds followed the 
pattern of compound 32. Compound 34 was able to antagonize all three opioid receptors with 
IC50 values 5.422.32 µM for δ, 183.736.5 nM for κ, and 424.458.65 nM for μ (Figure 47), 
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the antagonist potency of 34 was found to be 219.35 nM for δ, 113.50 nM for κ and 24.32 nM 
for µ (Figure 48).  Compound 35 shows Ki less than 400 nM just for µ, the antagonist potency of 
35 was found to be 195.8 nM (Figure 49). Compound 36 was able to antagonize both κ and μ 
opioid receptors with IC50 values 1068  213µM for κ, and 1692  575 nM for μ (Figure 50), the 
antagonist potency of 36 was found to be 216.29 nM for κ and 42.37 nM for µ (Figure 50) 
Compound 37 showed a significant preferential binding for κ with Ki 94.8410.31 nM, unlike 
other compounds 37 found to be partial agonist in к and antagonist in µ (Figure 51).. 
Figure 44. Shows the agonist assay of 32 were no agonist activity 
 
Figure 45. Shows the partial agonist activity of 33 
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I.4 CHEMISTRY 
The synthesis of indole-2-carboxamide 1 was achieved through the methods illustrated in 
Scheme 1.  
Scheme 1. Synthesis of indole -2-carboxamides
 
Reagent and conditions: (a) benzylamine, reflux 3 hr, 195 
o
C (b) NH4OH, 12 hr, rt (c) LAH, THF, 
reflux 18 hr (d) EDCI, DMA, CH2Cl2, 0 
o
C to rt, 24 hr (e) Pd/C, MeOH, 12 hr (f) NaBH(OAc)3, rt. 
 
The synthetic procedures for 1-Benzyl-5-oxo-3-pyrrolidinecarboxylates (1.2) is as 
follows: dimethyl itaconate (1.1) was reacted with equimolar of benzylamine. (1.2) was treated 
with aqueous ammonia to afford (1.3), which was reduced with lithium aluminium hydride to 
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give (1.4). 1.4 is coupled with the commercially available indole-2-carboxylic acids (1.5) in the 
presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 4-dimethylaminopyridine in 
CH2Cl2 to yield compound 4. Compound 4 was subjected to debenzylation fllowed by reductive 
amination with the commercially available 3-Hydroxybenzaldehyde (1.7) to yield the final 
compound 1. The analogues (1-8, 13-19) were prepared by debenzylation of 4 followed by 
reductive amination reactions with different aldehydes 1.7, Scheme 2. 
3-Pyrrolidinylmethylamine was subjected to Hofmann rearrangement using 
phenyliododiacetate (PIDA) to produce 3-aminopyrrolidine in order to prepare more analogues 
of compound (1), Scheme 3. 
Scheme 2. Syntheses of indole-2-carboxamide Analogues (1-8, 13-19) 
 
Reagent and conditions: (a) benzylamine, reflux 3 hr, 195 
o
C (b) NH4OH, 12 hr, rt (c) LAH, THF, reflux 
18 hr (d) EDCI, DMA, CH2Cl2, 0 
o
C to rt, 24 hr (e) Pd/C, MeOH, 12 hr (f) NaBH(OAc)3, rt. 
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Scheme 3.  Syntheses of indole-2-carboxamide Analogues (9-12, 20-26) 
 
Reagent and conditions: (a) benzylamine, reflux 3 hr, 195 
o
C (b) NH4OH, 12 hr, rt (c) PhI(OAc) 
H2O/MeCN, rt 1 hr (d)LAH, THF, reflux 18 hr (e) EDCI, DMA, CH2Cl2, 0 
o
C to rt, 24 hr (f) Pd/C, 
MeOH, 12 hr (g) NaBH(OAc)3, rt. 
 
Compounds 29-36 were prepared as shows in Schem 4. Compound 3.1 was produced by 
treating 1.2 with KOH solution for 30 minute. The commercially available analine or 4-
methylpyridin-2-amine was couple with compound 3.1 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide and 4-dimethylaminopyridine in CH2Cl2 to produce 
intermediate; reduction of 3.2 with lithium aluminium hydride give compounds 29 and 30.  Each 
of compounds 29 and 30 were a subject to couple reaction with variety of carboxylic acid 
analogues to produced compounds 31-33 and 37. The analogue (34- 36 and 38) were prepared by 
debenzylation of 32 followed by reductive amination reactions with 3-hydroxybenzaldehyde, 4-
hydroxybenzaldehyde and 2-phenylacetaldehyde, respectively. 
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Scheme 4.  Syntheses of derivatives (31-38) 
 
 
Reagent and conditions: (a) benzylamine, reflux 3 hr, 195 
o
C (b) 10% KOH, 30 min., rt (c) EDCI, 
DMA, CH2Cl2, 0 
o
C to rt, 24 hr (d) LAH, THF, reflux 18 hr (e) EDCI, DMA, CH2Cl2, 0 
o
C to rt, 24 hr (f) 
Pd/C, MeOH, 12 hr (g) NaBH(OAc)3, rt. 
Cycloaddition with a trisubstituted alkene 4.1 with trifluoromethylated azomethine 4.2 
furnished the fluorinated product 4.3. Saponification to the carboxylic acids was followed by 
coupling with analine to give 4.4 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide and Hydroxybenzotriazole in dry DMF. Reduction of 4.4 
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with lithium aluminium hydride gave 4.5. The compound 39 was prepared by coupling 2-Furoyl 
chloride with compound 4.5. 
Scheme 5. Synthesis of compound 39. 
 
Reagent and conditions: (a) TMS-OTf, DCM (b) aq NaOH, EtOH, THF (c) EDCI, HOBt, DMF rt, 12 hr 
(d) LAH, THF, reflux 18 hr (e) 2-Furoyl chloride, Et3N anhyd, DCM, rt. 12 hr. 
4.1 Experimental Section 
General Experimental Procedures. 
1
H and 
13
C NMR spectra were obtained on Bruker 
model AMX 500 and 400 NMR spectrometers with standard pulse sequences, operating at 500 
MHz in 
1
H and 125 MHz in 
13
C. CDCl3, DMSO-d6, and CD3OD were used as solvents and TMS 
was used as an internal standard. High-resolution mass spectra (HRMS) were recorded on a 
Micromass Q-Tof Micro mass spectrometer with a lock spray source. Column chromatography 
was carried out on silica gel (70-230 mesh, Merck). Fractions obtained from column 
chromatography were monitored by TLC (silica gel 60 F254). Preparative TLC was carried out 
on silica gel 60 PF254+366 plates (20 × 20 cm, 1 mm thick). All chemicals used were from 
Sigma-Aldrich (Poole, Dorset, U.K.) with the following exceptions. For the binding experiments, 
[
3
H]CP 55,940 (174.8 Ci/mmol), [
3
H]DAMGO (53.4 Ci/mmol), [
3
H]U-69,593 (42.7 Ci/mmol), 
[
3
H]Enkephlin (45 Ci/mmol), were obtained from Perkin-Elmer Life Sciences Inc. (Boston, MA, 
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U.S.A.). CP 55,940, DAMGO, DPDPE, nor-Binaltorphimine and Win 55,212-2 were obtained 
from Tocris Bioscience (Ellisville, Missouri, U.S.A.). 
Cell Culture. HEK293 cells (ATCC) were stably transfected with cannabinoid receptor 
subtypes 1 and 2, (obtained from Origene, Rockville, MD, U.S.A.). These cells were maintained 
in a humidified incubator at 37 
o
C and 5% CO2 in a Dulbecco’s Modified Eagles’s medium 
(DMEM) nutrient mixture F-12 HAM supplemented with 2 mM L-glutamine, 10% fetal bovine 
serum, 1000 IU/mL Penicillin and 1000 g/mL of Streptomycin, and 0.5 mg/mL G418 antibiotic 
solutions. HEK293 cells stably transfected with opioid receptor subtypes µ, δ, and κ, were used 
to perform the opioid receptor binding assays. These cells were maintained at 37 
o
C and 5% CO2 
in a DMEM nutrient mixture supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 
1000 IU/mL Penicillin and 1000 g/mL of Streptomycin, and either 0.5 mg/mL () or 0.2 
mg/mL ( or ) G418 antibiotic solutions. Membranes for the radioligand binding assays were 
prepared by scraping the cells in cold Tris-HCl, pH 7.4 and then centrifuged at 5,200 x g for 10 
min at 4°C. The supernatant was discarded and the pellet was resuspended in the same buffer and 
homogenized via Sonic Dismembrator Model 100 (Fisher Scientific, Pittsburgh, PA) for 30 
seconds and then centrifuged at 1,000 x g for 10 min at 4°C. The supernatant was saved and the 
pellet underwent the suspension and sonication process 2 more times with the same conditions. 
The supernatants were combined and centrifuged at 23,300 x g for 40 minutes at 4°C. The pellet 
was re-suspended and aliquoted into 2mL vials and stored at -80°C. The total protein 
concentration was determined using a Pierce BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL) using to manufactures instructions [207].
 
The optimal membrane and radioligand 
(KD) concentrations for each receptor batch was established through a membrane evaluation and 
saturation binding experiments. 
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Radioligand Displacement for Opioid Receptor Subtypes. All compounds evaluated in 
the assay were run in competition binding against the opioid receptor subtypes (δ, κ, µ). Opioid 
binding assays were performed under the following conditions: 10 μM of each compound 
independent triplicate dilutions was incubated with 0.85 nM [
3
H]-DAMGO (µ), 0.91 nM 
[Phenyl-3,4-
3
H]- U-69,593 (κ), or 0.99 nM [3H]-enkephalin (δ) for 60 minutes in a 96-well plate 
in a 0.2 mL final volume of 50mM Tris-HCl, pH 7.4 with 15 μg () or 20 μg (µ and ) of 
membrane. The reaction was terminated via rapid vacuum filtration through a Perkin Elmer 96-
well Unifilter GF/B filters presoaked with 0.3% BSA, followed by 10 washes with 50 mM Tris-
HCl, pH 7.4. Plates were read using a Perkin Elmer TopCount NXT Microplate scintillation 
counter. Total binding was defined as binding in the presence of vehicle (1.0% DMSO). 
Nonspecific binding was the binding observed in the presence of 10 μM DAMGO (µ), U-69,593 
(κ), or DPDPE (δ). Specific binding was defined as the difference between total and nonspecific 
binding. Percent binding was calculated using the following formula: 100-(binding of 
compound- nonspecific binding)*100/specific binding.  
The competitive binding assay was performed testing 12 triplicate 3-fold serial dilutions 
of 300 µM compound and 3 µM control (naloxone hydrochloride) with 15 µg of  membrane 
and 1.87 nM [
3
H]-DPDPE. The IC50 and Ki values were calculated by a non-linear curve fit 
model using GraphPad Prism 5.0 software (GraphPad, La Jolla, CA). 
In vitro GTPγS functional assay. The GTPγS functional assay was performed in GTPγS 
assay buffer (50 mM Tris-HCl, 150 mM NaCl, 9 mM MgCl2, 0.2 mM EGTA, 1.4 mg/mL 
essentially fatty acid free BSA) as previously described [244, 245] with some modifications. 
Each compound was tested in triplicate and controls in quadruplicate. Controls consisted of 
Emax (10 μM of non-labeled DPDPE), basal (vehicle only), and non-specific binding (40 μM of 
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non-labeled GTPγS salt). In addition to buffer and test compound/control, each 250 μL test well 
contained 10 μM GDP, 3% DMSO (i.e., vehicle), 25 μg membrane protein from HEK-293 cells 
stably transfected with human δ opioid receptor, and 50 pM [35S]-Guanosine 5’-(γ-thio) 
Triphosphate (PerkinElmer, Waltham, MA). Plates were incubated, harvested, dried, and 
radioactivity was quantified similar to the opioid binding assays. Percent over basal was 
calculated in Microsoft Excel by subtracting the mean basal control from the each value obtained 
in the presence of a ligand and then dividing by the mean basal control. The standard error of the 
mean (SEM) was calculated in Microsoft Excel by dividing the standard deviation by the square 
root of the count. 
Preparation of 1-Benzyl-5-oxo-3-pyrrolidinecarboxylates (1.2): A mixture of 
equimolecular amount of dimethyl itaconate (2 g 12.64 moles) and the benzylamine (1.35 g, 1.4 
mL) was heated at 195 
o
C for 3 hr, cooled to rt, then evaporated under reduced pressure. Ester 
1.2 used in next step without further purification [203]. 
1
H NMR (500 MHz, Methanol-d4) δ 7.59 
– 7.26 (m, 5H), 4.63 – 4.51 (m, 2H), 3.79 (s, 2H), 3.67 – 3.56 (m, 2H), 3.41 – 3.33 (m, 1H), 2.83 
(d, J = 8.0 Hz, 2H). 
13
C NMR (126 MHz, Methanol-d4) δ 174.75, 174.73, 137.33, 129.81, 
129.02, 128.75, 52.93, 49.88, 47.19, 36.79, 34.90. 
Preparation of 1-Benzyl-5-oxo-3-pyrrolidinecarboxamids (1.3): The ester 1.2 was 
stirred overnight with NH4OH (9 mL) at rt. Filtration yield amide 1.3 as a white soled (1.78g 
yield 65%) [204]. 
1
H NMR (400 MHz, DMSO-d6) δ 7.33 (t, J = 7.3 Hz, 2H), 7.24 (dd, J = 18.7, 
7.3 Hz, 3H), 4.36 (d, J = 3.3 Hz, 2H), 3.41 (t, J = 9.3 Hz, 1H), 3.27 (dd, J = 9.6, 6.2 Hz, 1H), 
3.10 (dd, J = 8.6, 6.2 Hz, 1H), 2.51 (d, J = 8.4 Hz, 2H).
13
C NMR (101 MHz, DMSO-d6) δ 
174.40, 172.60, 136.79, 128.63, 127.64, 127.32, 49.16, 45.41, 35.77, 33.94. 
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Preparation of 1- Benzyl-3-pyrrolidinylmethlamine (1.4): Amide 1.3 0.4 g (1.8 
mmoles) in THF 3mL was added dropwise to a suspension of LAH (0.278 g 7.33 mmoles) in 
THF 3 mL at 0 
o
C. after the addition was complete, the reaction mixture was refluxed for 18 h, 
cooled to 0 
o
C, and quenched carefully by addition 0.2mL H2O then 0.2mL of 15% NaOH 
finnaly 0.6mL H2O. The resulting white precipitate was removed by filtration, and the filtered 
was transferred to a separatory funnel. The layers were separated, and the aqueous layer was 
extracted with EtOAc. The organic extract and layer were combined, dried (NaSO4), and 
concentrated. Solution dried by evaporated under reduced pressure to give 0.282 g of amine 1.4. 
(81% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.23 – 7.13 (m, 4H), 7.10 (d, J = 6.4 Hz, 1H), 
3.45 (d, J = 2.6 Hz, 2H), 2.60 – 2.54 (t, 1H), 2.50 (d, 2H), 2.43 (t, J = 7.4 Hz, 1H), 2.37 (q, J = 
8.5, 7.6 Hz, 1H), 2.07 (m, 2H), 1.83 (m, 1H), 1.31 (m, 5.9 Hz, 1H). 
13
C NMR (101 MHz, 
Chloroform-d) δ 138.81, 128.27, 127.73, 126.38, 60.12, 57.79, 53.46, 46.47, 40.19, 28.02. 
Preparation of N-((1-benzylpyrrolidin-3-yl)methyl)-1H-indole-2-carboxamide (4) 
(Procedure B): DMAP (2.22 mmol, 0.272 g), indole-2-carboxylic acid (1.3512 mmol, 0.218 g) 
and EDCI (1.481 mmol, 0.2853 g) were added to a solution of 1.4 ( 1.482 mmol, 0.282 g) in 
dichloromethane (20 mL) at 0
o
C for 4 h and then at rt for 20 h. Soild NaHCO3 added to reaction 
mixture. Keep it stirring for 20 min then filtration the mixture. After evaporation of the solvent, 
the residue was purified by column chromatography on silica gel (eluent: DCM:MeOH 95:5) to 
give 4 (0.318 g 62%) as yellow oil [205]. 
1
H NMR (400 MHz, Methanol-d4) δ 7.59 (d, J = 8.1 
Hz, 1H), 7.46 (d, J = 8.3 Hz, 1H), 7.26 – 7.14 (m, 6H), 7.09 (s, 1H), 7.08 – 7.02 (m, 1H), 3.42 (s, 
2H), 3.34 (d, J = 7.2 Hz, 2H), 2.64 (m, 1H), 2.52 – 2.46 (m, 1H), 2.43 (t, 2H), 2.25 (dd, J = 9.7, 
6.2 Hz, 1H), 1.88 (m, 1H), 1.48 (m, 1H). 
13
C NMR (101 MHz, Methanol-d4) δ 164.25, 139.15, 
138.31, 132.28, 130.34, 129.35, 129.04, 128.36, 125.12, 122.86, 121.28, 113.23, 104.52, 61.40, 
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59.01, 54.60, 44.93, 38.44, 29.18. HRMS (ESI-TOF) m/z calcd for C21H24N3O [M+H]
+
: 
334.1914. Found: 334.2124. 
Preparation of N-(pyrrolidin-3-ylmethyl)-1H-indole-2-carboxamide (1.6): A solution 
of the known 4 (225 mg, 0.67 mmol ) and Pd/C (72 mg, 10% pd, 0.07 mmol) in degassed MeOH 
(20 mL) at 40 Psi H2 for 12 hr. The solids were removed by filtration through Celite and the filter 
cake was washed with MeOH (50 mL). The filtrate was evaporated under reduced pressure to 
give 1.6 as a yellow oil ( 173mg, 0.71 mmol, 100%) which was directly used for the next step. 
1
H NMR (400 MHz, Methanol-d4) δ 7.52 (d, J = 7.9 Hz, 1H), 7.44 (d, J = 8.1 Hz, 1H), 7.11 (q, J 
= 11.7, 9.5 Hz, 2H), 6.98 (q, 1H), 3.39 – 3.30 (m, 1H), 3.12 (dd, J = 11.7, 7.6 Hz, 1H), 3.08 – 
2.99 (m, 1H), 2.94 (dq, J = 11.6, 7.6, 6.1 Hz, 1H), 2.84 (dd, J = 11.6, 6.9 Hz, 1H), 2.47 (m, 1H), 
1.86 (m, 1H), 1.50 (m, 1H). 
13
C NMR (101 MHz, Methanol-d4) δ 164.34, 138.41, 132.18, 
128.94, 125.17, 122.83, 121.28, 113.30, 105.07, 50.00, 46.40, 42.74, 40.13, 29.90. 
Preparation of N-((1-(3-hydroxybenzyl)pyrrolidin-3-yl)methyl)-1H-indole-2-
carboxamide (1): Procedure A:To salicylaldehyde (0.19 mmol) and 1.6 (0.21 mmol) in THF 
was added sodiumtriacetoxy borohydride (0.31 mmol). The mixture was stirred at room 
temperature under an atmosphere of argon for 12 h and then, treated with aqueous NaOH (3N). 
The aqueous layer was extracted with Et2O and the organic layers were combined and dried over 
Na2SO4. Solvent was removed under vacuum and the crude product was purified on silica gel 
chromatography (CH2Cl2/ MeOH, 97:3) to afford compound 1 as a yellow oil (65mg, 62%) 
[206]. 
1
H NMR (400 MHz, DMSO-d6) δ 7.59 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.16 
(t, J = 7.6 Hz, 1H), 7.06 (dq, J = 21.5, 7.3 Hz, 3H), 6.76 – 6.68 (m, 2H), 6.61 (dd, J = 8.1, 2.4 
Hz, 1H), 3.47 (q, J = 13.1 Hz, 3H), 3.32 – 3.19 (m, 1H), 2.58 (t, J = 8.2 Hz, 1H), 2.53 (d, J = 7.7 
Hz, 0H), 2.43 (t, J = 7.8 Hz, 1H), 2.31 (dd, J = 9.0, 5.4 Hz, 1H), 1.98 – 1.80 (m, 1H), 1.49 (dt, J 
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= 12.4, 6.3 Hz, 1H). 
13
C NMR (101 MHz, DMSO-d6) δ 161.59, 157.68, 141.16, 136.80, 132.23, 
129.47, 127.52, 123.61, 121.85, 120.09, 119.43, 115.65, 114.15, 112.70, 102.79, 60.09, 58.25, 
53.74, 43.95, 37.57, 28.48. HRMS (ESI-TOF) m/z calcd for C21H24N3O2 [M+H]
+
: 350.1863. 
Found: 350.1982. 
N-((1-(4-hydroxybenzyl)pyrrolidin-3-yl)methyl)-1H-indole-2-carboxamide (2). The 
title compound was prepared from N-(pyrrolidin-3-ylmethyl)-1H-indole-2-carboxamide 1.6 
(50mg, 0.205 mmol) and 4-hydroxybenzaldehyde ( 0.185 mmol, 22.6 mg) according to 
procedure A. Crude product was purified on silica gel chromatography (CH2Cl2/ MeOH, 97:3) to 
afford compound 2 as a yellow oil (48mg, 66%). 
1
H NMR (500 MHz, Methanol-d4) δ 7.54 (d, J 
= 7.8 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.14 (t, J = 7.6 Hz, 1H), 7.02 (d, J = 12.8 Hz, 3H), 6.69 
(d, J = 7.9 Hz, 2H), 3.36 (s, 2H), 3.27 (q, J = 1.7 Hz, 0H), 2.63 (t, J = 8.6 Hz, 1H), 2.55 – 2.38 
(m, 2H), 2.22 (dd, J = 9.8, 6.0 Hz, 1H), 1.86 (s, 0H), 1.46 (dq, J = 13.3, 7.0 Hz, 1H). 
13
C NMR 
(126 MHz, Methanol-d4) δ 164.16, 159.44, 138.19, 132.20, 131.56, 128.90, 128.76, 124.98, 
122.71, 121.11, 116.70, 113.02, 104.60, 60.86, 58.72, 54.33, 44.84, 38.29, 29.09. HRMS (ESI-
TOF) m/z calcd for C21H24N3O2 [M+H]
+
: 350.1863. Found: 350.1969. 
N-((1-(2-chlorobenzyl)pyrrolidin-3-yl)methyl)-1H-indole-2-carboxamide (3). The 
title compound was prepared from N-(pyrrolidin-3-ylmethyl)-1H-indole-2-carboxamide 1.6 
(50mg, 0.205 mmol) and 2-chlorobenzaldehyde ( 0.185 mmol, 26.0 mg) according to procedure 
A. Crude product was purified on silica gel chromatography (CH2Cl2/ MeOH, 99:1) to afford 
compound 3 as a yellow oil (42mg, 55%). 
1
H NMR (400 MHz, Methanol-d4) δ 7.49 (dd, J = 8.0, 
1.1 Hz, 1H), 7.35 (d, J = 2.8 Hz, 1H), 7.34 – 7.32 (m, 1H), 7.27 – 7.23 (m, 1H), 7.17 – 7.07 (m, 
3H), 7.00 – 6.91 (m, 2H), 3.63 (s, 2H), 3.30 (d, J = 6.8 Hz, 2H), 2.68 (dd, J = 9.3, 7.4 Hz, 1H), 
2.61 – 2.54 (m, 1H), 2.54 – 2.41 (m, 2H), 2.37 (dd, J = 9.3, 5.8 Hz, 1H), 1.90 (m, J = 13.4, 9.5, 
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5.8, 3.9 Hz, 1H), 1.53 – 1.44 (m, 1H). 13C NMR (101 MHz, Methanol-d4) δ 164.43, 138.40, 
137.28, 135.31, 132.34, 130.60, 129.78, 129.10, 128.06, 125.13, 122.85, 121.27, 113.18, 104.48, 
59.33, 57.80, 54.89, 45.12, 38.67, 29.36. HRMS (ESI-TOF) m/z calcd for C21H23ClN3O [M+H]
+
: 
368.1524. Found: 368.1671. 
N-((1-(3-chlorobenzyl)pyrrolidin-3-yl)methyl)-1H-indole-2-carboxamide (5). The 
title compound was prepared from N-(pyrrolidin-3-ylmethyl)-1H-indole-2-carboxamide 1.6 
(50mg, 0.205 mmol) and 3-chlorobenzaldehyde ( 0.185 mmol, 26.0 mg) according to procedure 
A. Crude product was purified on silica gel chromatography (CH2Cl2/ MeOH, 99:1) to afford 
compound 5 as a yellow oil (45mg, 59%). 
1
H NMR (400 MHz, Methanol-d4) δ 7.55 (d, J = 7.9 
Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 1.7 Hz, 1H), 7.24 – 7.13 (m, 4H), 7.03 (s, 1H), 
7.01 (t, J = 7.3 Hz, 1H), 3.65 (s, 2H), 3.34 (dd, J = 6.7, 2.9 Hz, 2H), 2.84 (dd, J = 9.5, 7.2 Hz, 
1H), 2.67 (t, J = 7.1 Hz, 2H), 2.59 – 2.51 (m, 1H), 2.51 – 2.45 (m, 1H), 2.03 – 1.93 (m, 1H), 1.59 
(m, 1H). 
13
C NMR (101 MHz, Methanol-d4) δ 162.90, 140.46, 136.87, 133.82, 130.79, 129.47, 
128.77, 127.58, 127.17, 127.01, 123.60, 121.32, 119.74, 111.63, 102.91, 59.35, 57.62, 53.29, 
43.37, 37.23, 27.81. HRMS (ESI-TOF) m/z calcd for C21H23ClN3O [M+H]
+
: 368.1524. Found: 
368.1775. 
N-((1-(3-(trifluoromethyl)benzyl)pyrrolidin-3-yl)methyl)-1H-indole-2-carboxamide 
(6). The title compound was prepared from N-(pyrrolidin-3-ylmethyl)-1H-indole-2-carboxamide 
1.6 (50mg, 0.205 mmol) and 3-(trifluoromethyl)benzaldehyde ( 0.185 mmol, 32.2 mg) according 
to procedure A. Crude product was purified on silica gel chromatography (CH2Cl2/ MeOH, 99:1) 
to afford compound 6 as a yellow oil (43mg, 52%).
1
H NMR (400 MHz, Chloroform-d) δ 7.67 – 
7.60 (m, 2H), 7.56 (t, J = 8.6 Hz, 2H), 7.49 (dd, J = 8.3, 3.5 Hz, 1H), 7.42 (t, J = 7.7 Hz, 1H), 
7.28 (dd, J = 8.8, 6.5 Hz, 1H), 7.15 (t, J = 7.6 Hz, 1H), 6.89 (d, J = 3.9 Hz, 1H), 3.78 – 3.63 (m, 
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2H), 3.64 – 3.44 (m, 2H), 2.89 (td, J = 8.8, 4.0 Hz, 1H), 2.77 – 2.68 (m, 1H), 2.63 (dq, J = 11.8, 
5.7, 4.3 Hz, 2H), 2.45 (dd, J = 10.2, 6.4 Hz, 1H), 2.08 (m, 1H), 1.68 (m, 1H). 
13
C NMR (101 
MHz, Chloroform-d) δ 162.73, 136.87, 132.55, 131.17, 131.01, 130.69, 129.13, 127.72, 125.71, 
124.44, 124.36, 121.94, 120.61, 112.38, 102.58, 59.87, 58.65, 53.97, 44.78, 36.29, 28.03. HRMS 
(ESI-TOF) m/z calcd for C22H23F3N3O [M+H]
 +
: 402.1788 Found: 402.1970. 
N-((1-(3,5-dihydroxybenzyl)pyrrolidin-3-yl)methyl)-1H-indole-2-carboxamide (7). 
The title compound was prepared from N-(pyrrolidin-3-ylmethyl)-1H-indole-2-carboxamide 1.6 
(50mg, 0.205 mmol) and 3,5-dimethoxybenzaldehyde ( 0.185 mmol, 25.6 mg) according to 
procedure A. Crude product was purified on silica gel chromatography (CH2Cl2/ MeOH, 98:2) to 
give 7 as a yellow oil (51mg, 64%). 
1
H NMR (400 MHz, Chloroform-d) δ 7.64 (d, J = 8.0 Hz, 
1H), 7.46 (d, J = 8.2 Hz, 1H), 7.27 (t, J = 7.6 Hz, 1H), 7.13 (t, J = 7.5 Hz, 1H), 6.90 (s, 1H), 6.58 
(d, J = 2.1 Hz, 2H), 6.41 (d, J = 2.1 Hz, 1H), 3.71 (s, 6H), 3.66 (d, J = 7.0 Hz, 2H), 3.60 (d, J = 
19.0 Hz, 1H), 3.47 (d, J = 13.1 Hz, 1H), 3.08 (td, J = 8.9, 3.6 Hz, 1H), 2.87 (d, J = 6.8 Hz, 1H), 
2.64 (d, J = 7.1 Hz, 2H), 2.46 (q, J = 8.8 Hz, 1H), 2.17 – 2.07 (m, 1H), 1.78 – 1.69 (m, 1H). 13C 
NMR (101 MHz, Chloroform-d) δ 162.59, 161.11, 136.64, 131.31, 127.85, 124.35, 122.06, 
120.59, 112.23, 107.21, 102.66, 99.76, 60.67, 58.79, 55.48, 54.17, 44.95, 35.88, 27.91. . HRMS 
(ESI-TOF) m/z calcd for C21H23N3O3 [M+H] 
+
: 394.2125. Found: 394.2210. 
N-((1-(3-phenoxybenzyl)pyrrolidin-3-yl)methyl)-1H-indole-2-carboxamide (8). The 
title compound was prepared from N-(pyrrolidin-3-ylmethyl)-1H-indole-2-carboxamide 1.6 
(50mg, 0.205 mmol) and 3-phenoxybenzaldehyde ( 0.185 mmol, 36.7 mg) according to 
procedure A. Crude product was purified on silica gel chromatography (CH2Cl2/ MeOH, 97:2) to 
afford 8 as a yellow oil (38mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.64 (d, J = 7.9 Hz, 1H), 
7.47 (d, J = 8.2 Hz, 1H), 7.35 – 7.24 (m, 4H), 7.18 – 7.14 (m, 1H), 7.14 – 7.10 (m, 1H), 7.07 (dd, 
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J = 4.6, 2.6 Hz, 2H), 7.03 – 6.97 (m, 2H), 6.94 (dd, J = 8.1, 2.4 Hz, 1H), 6.86 (d, J = 2.0 Hz, 1H), 
3.67 (d, J = 10.2 Hz, 2H), 3.62 – 3.44 (m, 2H), 3.00 (td, J = 8.8, 3.6 Hz, 1H), 2.82 (d, J = 6.6 Hz, 
1H), 2.67 – 2.56 (m, 2H), 2.42 (q, J = 8.7 Hz, 1H), 2.10 (m, 1H), 1.70 (m, 1H).13C NMR (101 
MHz, Chloroform-d) δ 162.60, 157.61, 157.22, 136.67, 131.27, 129.99, 129.90, 127.82, 124.32, 
124.07, 123.48, 122.08, 120.56, 119.68, 119.06, 117.90, 112.27, 102.54, 60.11, 58.89, 54.04, 
45.05, 35.93, 27.95. HRMS (ESI-TOF) m/z calcd for C27H27N3O2 [M+H]
+
: 426.2176. Found: 
426.2313. 
Preparation 1-Benzyl 3-aminopyrrolidine (2.2): From amide 1.3 PhI(OAc)2 (1.9 g, 6.1 
mmol_was added to a solution of amide 1.3 ( 1 g, 4.58 mmol)in H2O (30 mL) and MeCN (30 
mL). the mixture was stirred for 1 h at room temperature before adding H2O (10 mL), then HCl 
(4 mL, 37%). The aqueous layer was washed with CH2Cl2 and water was removed under vacuum 
to give the hydrochloride of 2.1. (70%).
 1
H NMR (400 MHz, DMSO-d6) δ 6.63 (d, J = 7.5 Hz, 
1H), 6.61 – 6.56 (m, 0H), 6.54 (s, 2H), 3.62 (d, J = 15.1 Hz, 2H), 3.27 (s, 1H), 2.94 (dd, J = 11.5, 
7.3 Hz, 1H), 2.63 (dd, J = 11.2, 3.5 Hz, 1H), 2.18 (dd, J = 17.6, 8.6 Hz, 1H), 1.81 (dd, J = 17.5, 
4.0 Hz, 1H). 
13
C NMR (101 MHz, DMSO-d6) δ 172.95, 136.42, 129.90, 128.82, 51.55, 46.81, 
44.15, 36.49.
. 
Amide 2.1 0.9 g (4.73 mmoles) in THF 3mL was added dropwise to a suspension of LAH 
(0.36 g 9.46 mmoles) in THF 3 mL at 0 
o
C. After the addition was complete, the reaction mixture 
was refluxed for 3 h, cooled to 0 
o
C, and quenched carefully by addition 0.4 mL H2O then 0.4 
mL of 15% NaOH finnaly 0.12 mL H2O. The resulting white precipitate was removed by 
filtration, and the filtered was transferred to a separatory funnel. The layers were separated, and 
the aqueous layer was extracted with EtOAc. The organic extract and layer were combined, dried 
(NaSO4), and concentrated. Solution was dried by evaporation under reduced pressure to give 
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amine 2.2. (81% yield). 
1
H NMR (400 MHz, Chloroform-d) δ 7.69 – 7.62 (m, 4H), 7.59 (dt, J = 
7.1, 3.1 Hz, 1H), 3.92 (d, J = 2.5 Hz, 2H), 3.78 (ddt, J = 8.4, 6.1, 4.2 Hz, 1H), 3.05 (dd, J = 8.8, 
5.4 Hz, 1H), 3.00 (dd, J = 9.4, 6.5 Hz, 1H), 2.75 (td, J = 8.7, 6.7 Hz, 1H), 2.66 (dd, J = 9.6, 4.3 
Hz, 1H), 2.51 (ddd, J = 13.4, 8.3, 5.3 Hz, 1H), 1.86 – 1.75 (m, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 138.16, 128.45, 127.78, 126.56, 62.86, 59.87, 52.59, 50.09, 34.14. 
N-(1-benzylpyrrolidin-3-yl)-1H-indole-2-carboxamide (11) The title compound was 
prepared by coupling the commercially available indole-2-carboxylic acids V with compound 2.2 
in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDCI and 4-
dimethylaminopyridine DMAP in CH2Cl2  according to procedure B. Crude product was purified 
on silica gel chromatography (CH2Cl2/ MeOH, 99:1) to afford 11 as a yellow oil (43mg). 
1
H 
NMR (400 MHz, Chloroform-d) δ 7.52 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.21 (s, 
4H), 7.14 – 7.09 (m, 2H), 7.01 – 6.96 (m, 2H), 4.73 – 4.68 (m, 1H), 3.73 (s, 1H), 3.60 (d, J = 
12.7 Hz, 1H), 3.15 (d, J = 7.3 Hz, 1H), 2.95 (s, 1H), 2.60 (d, J = 3.9 Hz, 1H), 2.36 (d, J = 9.7 Hz, 
1H), 2.23 (dq, J = 12.9, 4.2 Hz, 1H), 1.83 (dt, J = 8.8, 4.4 Hz, 1H). 
13
C NMR (101 MHz, 
Chloroform-d) δ 161.55, 136.85, 134.11, 131.04, 129.88, 128.86, 128.58, 127.70, 124.30, 
122.09, 120.37, 112.15, 104.29, 59.36, 59.28, 52.40, 50.38, 48.08, 31.77. . HRMS (ESI-TOF) 
m/z calcd for C20H21N3O [M+H]
+
: 320.1763. Found: 320.1901. 
N-(1-(3-hydroxybenzyl)pyrrolidin-3-yl)-1H-indole-2-carboxamide (9): The title 
compound was prepared from N-(pyrrolidin-3-yl)-1H-indole-2-carboxamide 2.3 (50mg, 0.205 
mmol) and 3-hydroxybenzaldehyde ( 0.174 mmol, 21.3 mg) according to procedure A. Crude 
product was purified on silica gel chromatography (CH2Cl2/ MeOH, 97:3) to afford 9 as a yellow 
oil. 
1
H NMR (400 MHz, Methanol-d4) δ 7.54 (d, J = 8.1 Hz, 1H), 7.41 – 7.36 (m, 1H), 7.18 – 
7.10 (m, 1H), 7.09 (d, J = 2.8 Hz, 2H), 7.00 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H), 6.85 – 6.82 (m, 1H), 
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6.77 (ddd, J = 8.6, 6.9, 2.0 Hz, 2H), 4.56 (dq, J = 8.8, 4.4 Hz, 1H), 3.81 (s, 2H), 3.13 (dt, J = 
11.3, 6.7 Hz, 2H), 2.97 (dd, J = 11.2, 4.5 Hz, 1H), 2.79 (dt, J = 10.8, 7.8 Hz, 1H), 2.31 (m, 1H), 
1.98 – 1.85 (m, 3H). 13C NMR (101 MHz, Methanol-d4) δ 163.74, 158.88, 138.25, 136.23, 
131.70, 130.91, 128.81, 125.23, 122.81, 121.85, 121.24, 117.71, 116.73, 113.05, 105.13, 59.95, 
59.77, 53.58, 49.85, 31.43. HRMS (ESI-TOF) m/z calcd for C20H21N3O2 [M+H]
+
: 336.1707. 
Found: 336.1728.
 
N-(1-(3-(trifluoromethyl)benzyl)pyrrolidin-3-yl)-1H-indole-2-carboxamide (10): The 
title compound was prepared from N-(pyrrolidin-3-yl)-1H-indole-2-carboxamide 2.3 (50mg, 
0.205 mmol) and 3-(trifluoromethyl)benzaldehyde (0.130 mmol, 22.6 mg) according to 
procedure A. Crude product was purified on silica gel chromatography (CH2Cl2/ MeOH, 97:3) to 
afford 10 as a yellow oil. 
1
H NMR (400 MHz, Chloroform-d) δ 8.04 (dd, J = 8.2, 3.6 Hz, 1H), 
7.83 (dd, J = 8.0, 3.6 Hz, 3H), 7.76 – 7.68 (m, 3H), 7.62 (dd, J = 8.1, 3.5 Hz, 3H), 7.45 (td, J = 
7.6, 3.5 Hz, 1H), 7.31 (td, J = 7.5, 3.6 Hz, 1H), 5.03 (dd, J = 7.8, 3.8 Hz, 1H), 4.03 – 3.83 (m, 
3H), 3.30 (d, J = 3.9 Hz, 1H), 3.23 – 3.10 (m, 1H), 2.90 (ddd, J = 10.5, 6.9, 3.6 Hz, 1H), 2.60 (tq, 
J = 8.2, 4.2, 3.7 Hz, 2H), 2.10 (dq, J = 8.3, 4.5, 3.8 Hz, 1H). 
13
C NMR (101 MHz, Chloroform-d) 
δ 161.66, 137.14, 136.86, 132.80, 130.91, 129.21, 127.73, 126.19, 124.89, 124.41, 122.09, 
120.53, 112.22, 103.55, 59.99, 59.22, 52.72, 48.52, 32.16. HRMS (ESI-TOF) m/z calcd for 
C21H20F3N3O [M+H]
 +
: 388.1631. Found: 338.1611. 
N-(1-(3-chlorobenzyl)pyrrolidin-3-yl)-1H-indole-2-carboxamide (12): The title 
compound was prepared from N-(pyrrolidin-3-yl)-1H-indole-2-carboxamide 2.3 (50mg, 0.205 
mmol) and 3-chlorobenzaldehyde (0.171 mmol, 24.1 mg) according to procedure A. Crude 
product was purified on silica gel chromatography (CH2Cl2/ MeOH, 97:3) to afford 12 as a 
yellow oil. 
1
H NMR (400 MHz, Chloroform-d) δ 7.65 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 8.3 Hz, 
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1H), 7.35 (d, J = 1.9 Hz, 1H), 7.31 – 7.20 (m, 4H), 7.14 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 8.1 Hz, 
1H), 3.64 (s, 2H), 3.00 (dt, J = 9.2, 4.6 Hz, 1H), 2.86 (dd, J = 10.1, 2.8 Hz, 1H), 2.71 (dd, J = 
10.0, 6.4 Hz, 1H), 2.43 (ddd, J = 14.6, 7.2, 3.2 Hz, 1H), 2.40 – 2.34 (m, 1H), 1.86 (ddt, J = 15.0, 
7.7, 3.9 Hz, 1H).
13
C NMR (101 MHz, Chloroform-d) δ 161.57, 140.13, 136.80, 134.37, 130.94, 
129.84, 129.07, 127.74, 127.66, 127.15, 124.45, 122.02, 120.61, 112.28, 102.73, 60.62, 59.46, 
52.78, 48.99, 32.68. HRMS (ESI-TOF) m/z calcd for C20H20ClN3O [M+H]
+
:354.1368. Found 
354.1358. 
N-((1-benzylpyrrolidin-3-yl)methyl)-3,5,7-trimethyl-1H-indole-2-carboxamide (13): 
The title compound was prepared by coupling the commercially available 3,5,7-trimethyl-1H-
indole-2-carboxylic acid with compound 1.4 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 13 as a yellow oil (41 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.47 (t, 
J = 4.8 Hz, 1H), 7.34 (d, J = 2.7 Hz, 6H), 6.99 (s, 1H), 3.70 (d, J = 12.8 Hz, 1H), 3.59 (t, J = 6.8 
Hz, 3H), 2.66 (s, 3H), 2.61 (t, J = 8.2 Hz, 3H), 2.55 (s, 3H), 2.50 (s, 3H), 2.45 (d, J = 8.3 Hz, 
1H), 2.10 (m, 1H), 1.73 (m, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 163.63, 138.33, 133.71, 
128.93, 128.75, 128.54, 128.18, 127.34, 126.97, 126.72, 120.84, 116.85, 113.21, 60.12, 58.16, 
53.73, 44.95, 36.04, 27.94, 21.46, 16.56, 10.21. HRMS (ESI-TOF) m/z calcd for C24H30N3O
+
 
[M+H]
+
:376.2383. Found 376.2428. And calcd for [M-H]
- 
274.2232. Found 274.2210. 
N-((1-benzylpyrrolidin-3-yl)methyl)-6-ethyl-1H-indole-2-carboxamide (14): The title 
compound was prepared by coupling the commercially available 6-ethyl-1H-indole-2-carboxylic 
acid with compound 1.4 in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  according to procedure B. Crude product 
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was purified on silica gel chromatography (CH2Cl2/ MeOH, 99:1) to afford 14 as a yellow oil (39 
mg) 
1
H NMR (400 MHz, Chloroform-d) δ 7.49 (d, J = 8.2 Hz, 1H), 7.46 – 7.42 (m, 1H), 7.34 – 
7.29 (m, 3H), 7.23 (d, J = 6.8 Hz, 2H), 7.00 (s, 1H), 6.95 (d, J = 8.5 Hz, 1H), 3.99 – 3.81 (m, 
2H), 3.50 (d, J = 5.1 Hz, 2H), 3.13 (m, 2H), 2.98 (d, J = 8.6 Hz, 1H), 2.78 – 2.72 (m, 2H), 2.70 
(d, J = 7.5 Hz, 2H), 2.17 – 2.06 (m, 1H), 1.89 – 1.76 (m, 1H), 1.23 (dd, J = 8.6, 6.5 Hz, 3H). 13C 
NMR (101 MHz, Chloroform-d) δ 162.64, 141.26, 137.19, 130.63, 130.11, 129.18, 125.84, 
121.87, 121.71, 110.69, 104.31, 59.57, 57.71, 53.45, 43.11, 36.61, 29.49, 27.69, 16.18. HRMS 
(ESI-TOF) m/z calcd for C23H28N3O
+
 [M+H]
+
:362.2227. Found 362.2252. And calcd for [M-H]
- 
366.2076. Found 360.1964 
N-((1-benzylpyrrolidin-3-yl)methyl)-4-methyl-1H-indole-2-carboxamide (15): The 
title compound was prepared by coupling the commercially available 4-methyl-1H-indole-2-
carboxylic acid with compound 1.4 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 15 as a yellow oil (41mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.42 (d, 
J = 6.2 Hz, 2H), 7.31 (d, J = 7.1 Hz, 4H), 7.19 – 7.14 (m, 1H), 7.07 (s, 1H), 6.91 (d, J = 7.1 Hz, 
1H), 3.80 (d, J = 1.7 Hz, 2H), 3.58 – 3.48 (m, 2H), 3.05 (td, J = 9.3, 4.1 Hz, 1H), 2.93 (dd, J = 
10.1, 4.3 Hz, 1H), 2.82 (dd, J = 10.3, 7.7 Hz, 1H), 2.75 – 2.65 (m, 1H), 2.62 (t, J = 8.9 Hz, 1H), 
2.54 (s, 3H), 2.11 (m, 1H), 1.76 (m, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 162.65, 136.52, 
135.46, 131.59, 130.59, 129.59, 128.90, 128.36, 127.93, 124.61, 120.55, 109.86, 102.18, 59.97, 
58.08, 53.80, 43.97, 36.34, 27.86, 18.93. HRMS (ESI-TOF) m/z calcd for C22H26N3O
+
 
[M+H]
+
:348.2070. Found 348.2112. And calcd for [M-H]
-
 346.1919. Found 346.1822. 
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(N-((1-benzylpyrrolidin-3-yl)methyl)-5,7-dimethyl-1H-indole-2-carboxamide (16): 
The title compound was prepared by coupling the commercially available 5,7-dimethyl-1H-
indole-2-carboxylic acid with compound 1.4 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 16 as a yellow oil (36 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.42 
(dd, J = 7.8, 1.8 Hz, 2H), 7.38 – 7.31 (m, 3H), 7.26 (d, J = 6.3 Hz, 1H), 6.92 (s, 1H), 6.83 (d, J = 
2.1 Hz, 1H), 3.75 (t, J = 12.6 Hz, 2H), 3.58 – 3.52 (m, 1H), 3.46 (dt, J = 13.3, 4.4 Hz, 1H), 3.04 
(dd, J = 9.2, 3.8 Hz, 1H), 2.89 (dd, J = 10.0, 3.5 Hz, 1H), 2.72 (t, J = 8.7 Hz, 1H), 2.67 – 2.61 
(m, 1H), 2.53 (s, 1H), 2.49 (s, 3H), 2.42 (s, 3H), 2.11 (m, 1H), 1.73 (m, 1H).. 
13
C NMR (101 
MHz, Chloroform-d) δ 162.66, 134.75, 131.03, 130.18, 129.51, 128.85, 128.09, 127.72, 126.83, 
121.25, 118.92, 103.08, 60.26, 58.65, 53.91, 44.60, 36.06, 27.90, 21.62, 17.01. . HRMS (ESI-
TOF) m/z calcd for C23H28N3O
+
 [M+H]
+
:362.2227. Found 362.2250. And calcd for [M-H]
-
 
360.2076. Found 360.2262. 
N-((1-benzylpyrrolidin-3-yl)methyl)-4,6-dimethyl-1H-indole-2-carboxamide (17): 
The title compound was prepared by coupling the commercially available 4,6-dimethyl-1H-
indole-2-carboxylic acid with compound 1.4 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 17 as a yellow oil ( 28mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.39 (d, 
J = 6.8 Hz, 2H), 7.32 (t, J = 7.1 Hz, 2H), 7.29 – 7.25 (m, 1H), 7.08 (s, 1H), 6.95 (s, 1H), 6.80 (s, 
1H), 3.67 (s, 2H), 3.61 – 3.55 (m, 1H), 3.53 – 3.47 (m, 1H), 2.92 (td, J = 8.8, 3.9 Hz, 1H), 2.72 
(q, J = 7.5 Hz, 1H), 2.62 (t, J = 6.4 Hz, 1H), 2.54 (s, 3H), 2.44 (s, 3H), 2.39 (d, J = 8.7 Hz, 1H), 
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2.09 (m, 1H), 1.68 (m, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 162.71, 138.35, 136.97, 
134.30, 130.82, 130.10, 128.95, 128.46, 127.29, 125.76, 122.56, 109.51, 101.04, 60.49, 58.65, 
54.08, 44.95, 36.03, 28.04, 21.93, 18.74. HRMS (ESI-TOF) m/z calcd for C23H28N3O
+
 
[M+H]
+
:362.2227. Found 362.2278.  
N-((1-benzylpyrrolidin-3-yl)methyl)-7-chloro-1H-indole-2-carboxamide (18): The 
title compound was prepared by coupling the commercially available 7-chloro-1H-indole-2-
carboxylic acid with compound 1.4 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 18 as a yellow oil (21mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.53 (d, 
J = 7.9 Hz, 1H), 7.36 (d, J = 2.0 Hz, 2H), 7.34 – 7.31 (m, 2H), 7.31 (d, J = 3.6 Hz, 1H), 7.27 (d, 
J = 7.6 Hz, 1H), 7.07 (t, J = 7.8 Hz, 1H), 6.89 (d, J = 1.8 Hz, 1H), 3.72 – 3.58 (m, 2H), 3.58 – 
3.40 (m, 2H), 3.00 – 2.87 (m, 1H), 2.74 (d, J = 7.4 Hz, 1H), 2.62 – 2.52 (m, 2H), 2.36 (q, J = 8.7 
Hz, 1H), 2.08 (dtd, J = 13.0, 9.0, 3.8 Hz, 1H), 1.64 (dtd, J = 12.0, 8.2, 3.5 Hz, 1H). 
13
C NMR 
(101 MHz, Chloroform-d) δ 161.95, 138.46, 133.85, 132.21, 129.10, 128.50, 127.39, 123.53, 
121.21, 120.49, 117.38, 103.52, 60.47, 59.05, 53.94, 45.41, 35.60, 27.94. . HRMS (ESI-TOF) 
m/z calcd for C21H23ClN3O
+
 [M+H]
+
:368.1524. Found 368.1585. And calcd for [M-H]
-
 
366.1373. Found 366.1488. 
N-((1-benzylpyrrolidin-3-yl)methyl)-5-hydroxy-1H-indole-2-carboxamide (19): The 
title compound was prepared by coupling the commercially available 5-hydroxy-1H-indole-2-
carboxylic acid with compound 1.4 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
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MeOH, 99:1) to afford 19 as a yellow oil (24 mg). 
1
H NMR (400 MHz, Methanol-d4) δ 6.95 (d, J 
= 8.8 Hz, 1H), 6.91 – 6.86 (m, 4H), 6.83 (q, J = 4.2 Hz, 1H), 6.66 (d, J = 2.3 Hz, 1H), 6.59 (s, 
1H), 6.51 (dd, J = 8.8, 2.3 Hz, 1H), 3.12 (s, 2H), 3.00 (d, J = 6.9 Hz, 2H), 2.34 – 2.30 (m, 1H), 
2.14 (d, J = 6.9 Hz, 3H), 1.96 – 1.92 (m, 1H), 1.56 (m, 1H), 1.19 – 1.12 (m, 1H). 13C NMR (101 
MHz, Methanol-d4) δ 164.19, 156.26, 152.55, 148.69, 139.29, 133.37, 132.78, 130.37, 129.81, 
129.40, 128.39, 116.25, 113.89, 106.04, 103.79, 61.44, 59.09, 54.68, 44.95, 38.52, 29.24. . 
HRMS (ESI-TOF) m/z calcd for C21H24N3O2 [M]
+
:350.1863. Found 350.1828. And calcd for 
[M]
-
 348.1712. Found 348.1779. 
N-((1-benzylpyrrolidin-3-yl)methyl)-6-(dimethylamino)-1H-indole-2-carboxamide 
(20): The title compound was prepared by coupling the commercially available 5-hydroxy-1H-
indole-2-carboxylic acid with compound 2.2 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 20 as a yellow oil (19 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.48 (d, 
J = 8.9 Hz, 1H), 7.41 – 7.31 (m, 5H), 6.94 (s, 1H), 6.77 (dd, J = 8.9, 2.2 Hz, 1H), 6.61 (s, 1H), 
4.80 (s, 1H), 3.83 (s, 2H), 3.23 (q, J = 8.5, 6.4 Hz, 1H), 3.02 (d, J = 10.8 Hz, 1H), 2.97 (s, 6H), 
2.79 (s, 1H), 2.52 (d, J = 8.6 Hz, 1H), 2.46 – 2.37 (m, 1H), 1.98 – 1.90 (m, 1H). 13C NMR (101 
MHz, Chloroform-d) δ 161.48, 149.54, 138.58, 129.58, 128.95, 128.66, 128.42, 122.59, 119.95, 
110.76, 93.89, 60.46, 59.73, 52.67, 48.34, 41.54, 32.30. HRMS (ESI-TOF) m/z calcd for 
C23H28N4O [M+H]
+
:363.2185. Found 363.2198. And calcd for [M-H]
-
 361.2028. Found 
361.2106. 
N-(1-benzylpyrrolidin-3-yl)-5,7-dimethyl-1H-indole-2-carboxamide (21): The title 
compound was prepared by coupling the commercially available 5,7-dimethyl-1H-indole-2-
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carboxylic acid with compound 2.2 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 21 as a yellow oil (16 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.36 (d, 
J = 4.4 Hz, 4H), 7.33 – 7.28 (m, 1H), 7.27 (d, J = 2.2 Hz, 1H), 7.16 (d, J = 8.3 Hz, 1H), 6.91 (s, 
1H), 6.89 (d, J = 2.1 Hz, 1H), 4.87 – 4.65 (m, 1H), 3.71 (s, 2H), 3.05 (td, J = 8.9, 8.5, 2.8 Hz, 
1H), 2.87 (dd, J = 10.1, 2.5 Hz, 1H), 2.69 (dd, J = 10.2, 6.3 Hz, 1H), 2.46 (s, 3H), 2.42 (s, 3H), 
2.40 – 2.34 (m, 1H), 1.85 (m, 1H).13C NMR (101 MHz, Chloroform-d) δ 161.46, 137.43, 134.83, 
130.72, 130.16, 129.20, 128.66, 127.72, 127.67, 126.89, 121.20, 118.93, 102.91, 60.72, 60.07, 
52.74, 48.71, 32.55, 21.55, 16.88. HRMS (ESI-TOF) m/z calcd for C22H26N3O 
[M+H]
+
:348.2070. Found 348.2070. And calcd for [M-H]
-
 346.1919. Found 346.1919. 
N-(1-benzylpyrrolidin-3-yl)-6-methyl-1H-indole-2-carboxamide (22): The title 
compound was prepared by coupling the commercially available 6-methyl-1H-indole-2-
carboxylic acid with compound 2.2 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 22 as a yellow oil (19 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.57 (d, 
J = 8.1 Hz, 1H), 7.49 – 7.34 (m, 6H), 7.06 – 6.98 (m, 2H), 4.93 – 4.81 (m, 1H), 3.88 (d, J = 7.8 
Hz, 2H), 3.27 (td, J = 9.2, 8.7, 4.1 Hz, 1H), 3.08 (d, J = 10.7 Hz, 1H), 2.83 (dd, J = 10.6, 6.6 Hz, 
1H), 2.57 (d, J = 8.5 Hz, 1H), 2.49 (s, 3H), 2.46 (m, 1H), 2.01 (m, 1H).
13
C NMR (101 MHz, 
Chloroform-d) δ 161.19, 136.89, 135.34, 134.51, 130.05, 129.36, 128.82, 128.74, 128.19, 
125.51, 122.59, 121.66, 111.62, 103.31, 60.21, 59.57, 52.45, 48.25, 32.11, 21.91. HRMS (ESI-
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TOF) m/z calcd for C21H24N3O [M+H]
+
:334.1919. Found 334.1938. And calcd for [M-H]
-
 
332.1763. Found 332.1791. 
N-(1-benzylpyrrolidin-3-yl)-5,7-dichloro-1H-indole-2-carboxamide (23): The title 
compound was prepared by coupling the commercially available 5,7-dichloro-1H-indole-2-
carboxylic acid with compound 2.2 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to rocedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 21 as a yellow oil (19 mg).
 1
H NMR (400 MHz, Chloroform-d) δ 7.49 (d, 
J = 1.7 Hz, 1H), 7.36 – 7.29 (m, 5H), 7.25 (d, J = 1.8 Hz, 1H), 6.91 (s, 1H), 4.77 (m, 1H), 3.73 
(s, 2H), 3.09 (dt, J = 9.3, 4.5 Hz, 1H), 2.96 – 2.87 (m, 1H), 2.69 (dd, J = 10.3, 6.3 Hz, 1H), 2.41 
(tt, J = 8.9, 6.0 Hz, 2H), 1.86 (m, 1H).
13
C NMR (101 MHz, Chloroform-d) δ 160.26, 137.02, 
132.99, 132.47, 129.39, 129.26, 128.73, 127.89, 126.19, 124.03, 120.09, 117.98, 103.27, 60.61, 
60.02, 52.68, 48.88, 32.47. HRMS (ESI-TOF) m/z calcd for C20H19Cl2N3O [M+H]
+
:388.0978. 
Found 388.1013. And calcd for [M-H]
-
 386.0827. Found 386.0847. 
N-(1-benzylpyrrolidin-3-yl)-4,6-dimethyl-1H-indole-2-carboxamide (24): The title 
compound was prepared by coupling the commercially available 4,6-dimethyl-1H-indole-2-
carboxylic acid with compound 2.2 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2 
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 24 as a yellow oil (17 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.38 – 
7.30 (m, 5H), 7.04 (s, 1H), 6.98 (d, J = 2.0 Hz, 1H), 6.81 (s, 1H), 4.82 (dtd, J = 8.6, 5.8, 3.3 Hz, 
1H), 3.69 (s, 2H), 3.03 (dt, J = 9.1, 4.7 Hz, 1H), 2.93 (dd, J = 10.1, 2.7 Hz, 1H), 2.71 (dd, J = 
10.2, 6.6 Hz, 1H), 2.55 (s, 3H), 2.45 (s, 3H), 2.43 – 2.33 (m, 2H), 1.89 (dp, J = 12.6, 4.1 Hz, 
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1H). 
13
C NMR (101 MHz, Chloroform-d) δ 161.73, 137.85, 137.06, 134.44, 130.98, 129.87, 
129.11, 128.48, 127.42, 125.77, 122.61, 109.48, 101.50, 60.66, 60.15, 52.83, 48.81, 32.60, 21.97, 
18.70. HRMS (ESI-TOF) m/z calcd for C22H26N3O [M+H]
+
:348.2076. Found 348.2161. And 
calcd for [M-H]
-
 346.1919. Found 346.1933. 
N-(1-benzylpyrrolidin-3-yl)-4-methyl-1H-indole-2-carboxamide (25):  The title 
compound was prepared by coupling the commercially available 4-methyl-1H-indole-2-
carboxylic acid with compound 2.2 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 25 as a yellow oil (21 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.35 (d, 
J = 3.3 Hz, 4H), 7.33 – 7.27 (m, 2H), 7.20 (dd, J = 8.3, 6.9 Hz, 1H), 7.04 (s, 1H), 6.97 – 6.93 (m, 
1H), 4.85 – 4.79 (m, 1H), 3.73 – 3.63 (m, 2H), 3.05 (td, J = 8.9, 3.2 Hz, 1H), 2.94 (dd, J = 10.2, 
2.3 Hz, 1H), 2.67 (dd, J = 10.3, 6.7 Hz, 1H), 2.58 (s, 3H), 2.42 (m, 1H), 2.34 (q, J = 8.5 Hz, 1H), 
1.86 (m, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 161.63, 137.57, 136.60, 136.45, 131.43, 
130.48, 129.19, 128.53, 127.88, 127.84, 127.54, 124.42, 120.36, 109.80, 109.75, 101.57, 60.75, 
60.21, 52.89, 48.64, 48.52, 32.49, 18.76. HRMS (ESI-TOF) m/z calcd for C21H24N3O 
[M+H]
+
:334.1919. Found 334.1963. And calcd for [M-H]
-
 332.1763. Found 332.1771. 
N-(1-benzylpyrrolidin-3-yl)-3,5,7-trimethyl-1H-indole-2-carboxamide (26): The title 
compound was prepared by coupling the commercially available 3,5,7-trimethyl-1H-indole-2-
carboxylic acid with compound 2.2 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  
according to procedure B. Crude product was purified on silica gel chromatography (CH2Cl2/ 
MeOH, 99:1) to afford 26 as a yellow oil (18 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.40 – 
103 
 
7.29 (m, 5H), 7.03 (d, J = 8.0 Hz, 1H), 6.93 (s, 1H), 4.77 (ddd, J = 12.8, 7.0, 3.8 Hz, 1H), 3.77 – 
3.65 (m, 2H), 3.08 (tt, J = 10.2, 5.8 Hz, 1H), 2.89 (dd, J = 10.1, 2.3 Hz, 1H), 2.70 (dd, J = 10.1, 
6.0 Hz, 1H), 2.60 (s, 3H), 2.46 (s, 6H), 2.44 – 2.35 (m, 2H), 1.93 – 1.83 (m, 1H). 13C NMR (101 
MHz, Chloroform-d) δ 162.35, 137.32, 133.73, 129.38, 129.06, 128.66, 128.64, 127.76, 127.07, 
127.00, 121.04, 117.04, 113.52, 60.55, 59.80, 52.43, 48.98, 32.59, 21.63, 16.78, 10.48. HRMS 
(ESI-TOF) m/z calcd for C23H28N3O [M+H]
+
:362.2232. Found 362.2234. And calcd for [M-H]
-
 
360.2076. Found 360.2105. 
1-benzyl-5-oxopyrrolidine-3-carboxylic acid 3.1:A solution of compound 3 (1.84 g; 7 
mmol) in THF (10 mL) was dissolved in 10 mL THF was treated with 10% KOH (10 mL) at 
room temperature for 30 min. THF was removed and the residue was acidified with 6 N HCl to 
pH 2, then extracted with ethyl acetate (2 x 15 mL). The combined organic layers were washed 
with brine (2 x 15 mL) and dried over anhydrous sodium sulfate. The solvent was removed to 
give compound 13 as a white solid. 1H NMR (400 MHz, Methanol-d4) δ 7.31 – 7.17 (m, 6H), 
4.46 – 4.34 (m, 2H), 3.51 – 3.42 (m, 2H), 3.23 – 3.13 (m, 1H), 2.70 – 2.62 (m, 2H). 13C NMR 
(101 MHz, Methanol-d4) δ 176.15, 175.46, 137.34, 129.90, 129.06, 128.84, 50.36, 47.37, 36.91, 
35.17. 
1-benzyl-N-(4-methylpyridin-2-yl)-5-oxopyrrolidine-3-carboxamide 3.2. DMAP (2.22 
mmol, 0.272 g), 3.1 (1.3512 mmol, 0.218 g) and EDCI (1.481 mmol, 0.2853 g) were added to a 
solution of 2-amino-4-methylpyridine or analine (1.482 mmol, 0.282 g) in dichloromethane (20 
mL) at 0
o
C for 4 h and then at rt for 20 h. Soild NaHCO3 added to reaction mixture.  It was kept 
stirring for 20 min then the mixture was filtered. After evaporation of the solvent, the residue 
was purified by column chromatography on silica gel (eluent: DCM:MeOH 9:1) to give 3.2 
(0.318 g 72%) as an yellow oil. 
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N-((1-benzylpyrrolidin-3-yl)methyl)furan-2-carboxamide 27: The title compound was 
prepared by coupling the commercially available furan-2-carboxylic acid with compound 1.4 in 
the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDCI and 4-
dimethylaminopyridine DMAP in CH2Cl2  according to procedure B. Crude product was purified 
on silica gel chromatography (CH2Cl2/ MeOH, 98:2) to afford 27 as a yellow oil (32 mg).
1
H 
NMR (400 MHz, Chloroform-d) δ 7.41 (s, 1H), 7.36 (d, J = 7.7 Hz, 2H), 7.27 (t, J = 7.4 Hz, 3H), 
7.24 – 7.18 (m, 1H), 7.05 (t, J = 2.4 Hz, 1H), 6.44 (dd, J = 3.4, 1.9 Hz, 1H), 3.61 (q, J = 12.8 Hz, 
2H), 3.48 – 3.30 (m, 2H), 2.82 (td, J = 8.8, 4.0 Hz, 1H), 2.58 (dt, J = 12.0, 5.8 Hz, 2H), 2.54 – 
2.47 (m, 1H), 2.35 (q, J = 8.4 Hz, 1H), 2.07 – 1.96 (m, 1H), 1.58 (m, 1H). 13C NMR (101 MHz, 
Chloroform-d) δ 158.92, 148.30, 143.63, 138.53, 128.74, 128.23, 127.09, 113.64, 111.96, 60.20, 
58.50, 53.78, 44.45, 35.87, 27.94. HRMS (ESI-TOF) m/z calcd for C17H20N2O2 
[M+H]
+
:285.1598. Found 285.1594.  
N-(1-benzylpyrrolidin-3-yl)furan-2-carboxamide 28 :The title compound was prepared 
by coupling the commercially available furan-2-carboxylic acid with compound 2.2 in the 
presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDCI and 4-
dimethylaminopyridine DMAP in CH2Cl2  according to procedure B. Crude product was purified 
on silica gel chromatography (CH2Cl2/ MeOH, 99:1) to afford 28 as a yellow oil ( 29 mg).
1
H 
NMR (400 MHz, Chloroform-d) δ 7.38 (d, J = 1.6 Hz, 1H), 7.28 (q, J = 7.3 Hz, 4H), 7.24 – 7.19 
(m, 1H), 7.05 (d, J = 3.5 Hz, 1H), 6.41 (dd, J = 3.5, 1.7 Hz, 1H), 4.60 (tq, J = 8.2, 4.1 Hz, 1H), 
3.62 (d, J = 1.6 Hz, 2H), 2.87 (m, 1H), 2.71 – 2.63 (m, 2H), 2.39 – 2.32 (m, 1H), 2.29 (m, 1H), 
1.72 (m, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 157.74, 147.92, 143.85, 137.96, 128.83, 
128.31, 127.21, 113.96, 111.94, 60.43, 59.85, 52.52, 48.16, 32.30. HRMS (ESI-TOF) m/z calcd 
for C16H18N2O2 [M+H]
+
:271.1441. Found 271.1417. 
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N-((1-benzylpyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine 29 & 30: Amide XII 
0.4 g (1.8 mmoles) in THF 3mL was added dropwise to a suspension of LAH ( 0.278 g 7.33 
mmoles) in THF 3 mL at 0 
o
C. after the addition was complete, the reaction mixture was 
refluxed for 18 h, cooled to 0 
o
C, and quenched carefully by addition 0.2mL H2O then 0.2mL of 
15% NaOH finnaly 0.6mL H2O. The resulting white precipitate was removed by filtration, and 
the filtered was transferred to a separator funnel. The layers were separated, and the aqueous 
layer was extracted with EtOAc. The organic extract and layer were combined, dried (NaSO4), 
and concentrated. Solution dried by evaporated under reduced pressure to give amine 29. (81% 
yield) and 30 (79%).  
N-((1-benzylpyrrolidin-3-yl)methyl)aniline (29). 
1
H NMR (400 MHz, Chloroform-d) δ 
7.47 – 7.39 (m, 4H), 7.37 – 7.32 (m, 1H), 7.26 (t, J = 7.7 Hz, 2H), 6.77 (t, J = 7.3 Hz, 1H), 6.67 
(d, J = 8.0 Hz, 2H), 3.71 (d, J = 2.7 Hz, 2H), 3.17 (t, J = 4.7 Hz, 2H), 2.81 (td, J = 8.7, 4.8 Hz, 
1H), 2.73 (td, J = 9.3, 2.6 Hz, 1H), 2.62 – 2.51 (m, 3H), 2.13 (m, 1H), 1.71 (m, 1H). 13C NMR 
(101 MHz, Chloroform-d) δ 148.69, 139.06, 129.30, 128.85, 128.40, 127.13, 116.98, 112.51, 
60.47, 58.57, 54.09, 49.07, 36.83, 28.59. HRMS (ESI-TOF) m/z calcd for C18H23N2 
[M+H]
+
:267.1856 Found 267.1863. 
N-((1-benzylpyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine (30). 
1
H NMR (400 
MHz, Chloroform-d) δ 7.91 (d, J = 5.2 Hz, 1H), 7.38 – 7.22 (m, 5H), 6.38 (dd, J = 5.2, 1.3 Hz, 
1H), 6.20 (s, 1H), 3.72 – 3.61 (m, 2H), 3.30 – 3.22 (m, 2H), 3.01 (s, 1H), 2.80 – 2.66 (m, 2H), 
2.60 – 2.47 (m, 3H), 2.21 (s, 3H), 2.05 (dtd, J = 13.3, 8.4, 5.0 Hz, 1H), 1.69 – 1.57 (m, 1H). 13C 
NMR (101 MHz, Chloroform-d) δ 159.02, 148.34, 147.42, 138.07, 128.93, 128.35, 127.24, 
114.19, 107.15, 60.17, 58.10, 53.82, 46.81, 36.82, 28.31, 21.17. HRMS (ESI-TOF) m/z calcd for 
C18H24N3 [M+H]
+
:282.1965. Found 282.1975  
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N-((1-benzylpyrrolidin-3-yl)methyl)-N-phenyl-1H-indole-2-carboxamide (31). The 
title compound was prepared by coupling the commercially available 1H-indole-2-carboxylic 
acid with compound 29 in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDCI and 4-dimethylaminopyridine DMAP in CH2Cl2  according to the procedure B. The crude 
product was purified on silica gel chromatography (CH2Cl2/ MeOH, 99:1) to afford 31 as a 
yellow oil (23 mg). 
1
H NMR (400 MHz, Chloroform-d) δ 7.49 (dd, J = 4.9, 1.9 Hz, 2H), 7.42 
(dd, J = 35.4, 8.4 Hz, 2H), 7.34 – 7.29 (m, 5H), 7.29 – 7.25 (m, 1H), 7.23 (t, J = 7.4 Hz, 1H), 
7.02 (d, J = 7.5 Hz, 1H), 5.20 (s, 1H), 4.14 – 3.97 (m, 2H), 3.69 – 3.58 (m, 2H), 2.83 – 2.79 (m, 
1H), 2.60 (td, J = 8.6, 6.4 Hz, 2H), 2.40 (dd, J = 9.3, 6.5 Hz, 1H), 2.05 – 1.96 (m, 1H), 1.71 – 
1.64 (m, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 162.33, 162.31, 142.54, 138.90, 135.60, 
135.46, 129.99, 129.81, 129.68, 129.10, 129.00, 128.75, 128.40, 127.78, 127.73, 127.14, 124.58, 
122.31, 120.26, 111.86, 111.81, 107.24, 107.19, 60.56, 58.30, 54.65, 53.76, 36.27, 28.62. HRMS 
(ESI-TOF) m/z calcd for C27H27N3O [M+H]
+
:410.2227. Found 410.2208.  
N-((1-benzylpyrrolidin-3-yl)methyl)-N-phenylfuran-2-carboxamide (32). The title 
compound was prepared by coupling the commercially available furan-2-carboxylic acid with 
compound 29 in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDCI and 4-
dimethylaminopyridine DMAP in CH2Cl2  according to the procedure B. The crude product was 
purified on silica gel chromatography (CH2Cl2/ MeOH, 99:1) to afford 32 as a yellow oil (27 
mg).
1
H NMR (400 MHz, Chloroform-d) δ 7.37 (dt, J = 8.2, 4.0 Hz, 5H), 7.33 – 7.29 (m, 2H), 
7.29 – 7.22 (m, 1H), 7.19 – 7.12 (m, 2H), 6.16 (dd, J = 3.5, 1.7 Hz, 1H), 5.65 (d, J = 3.5 Hz, 1H), 
3.92 (d, J = 7.6 Hz, 2H), 3.70 (t, J = 13.2 Hz, 2H), 2.90 (t, J = 8.6 Hz, 1H), 2.83 – 2.73 (m, 1H), 
2.66 – 2.61 (m, 1H), 2.60 – 2.54 (m, 1H), 2.47 – 2.40 (m, 1H), 2.01 – 1.92 (m, 1H), 1.67 – 1.58 
(m, 1H).
13
C NMR (101 MHz, Chloroform-d) δ 159.53, 147.00, 144.49, 142.37, 129.76, 129.28, 
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128.54, 128.44, 128.30, 127.60, 116.53, 111.08, 60.18, 57.87, 53.72, 53.37, 36.27, 28.37. HRMS 
(ESI-TOF) m/z calcd for C23H24N2O2[M+H]+:361.1911. Found 361.1912.  
N-((1-benzylpyrrolidin-3-yl)methyl)-N-phenylpropionamide 33: The title compound 
was prepared by coupling the commercially available propionic acid with compound 29 in the 
presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide EDCI and 4-
dimethylaminopyridine DMAP in CH2Cl2  according to procedure B. Crude product was purified 
on silica gel chromatography (CH2Cl2/ MeOH, 99:1) to afford 33 as a yellow oil (29 mg).
 1H 
NMR (400 MHz, Chloroform-d) δ 7.40 – 7.23 (m, 8H), 7.12 – 7.10 (m, 2H), 3.76 (dd, J = 7.6, 
3.5 Hz, 2H), 3.73 – 3.63 (m, 2H), 2.85 (t, J = 8.5 Hz, 1H), 2.76 (q, J = 7.9 Hz, 1H), 2.58 (q, J = 
8.2 Hz, 1H), 2.47 – 2.37 (m, 1H), 2.32 (dd, J = 9.5, 7.1 Hz, 1H), 2.00 (d, J = 7.4 Hz, 1H), 1.97 – 
1.87 (m, 1H), 1.55 (td, J = 7.6, 2.9 Hz, 1H), 1.01 (t, J = 7.4 Hz, 3H). 
13
C NMR (101 MHz, 
Chloroform-d) δ 174.13, 142.54, 129.82, 129.22, 128.47, 128.33, 128.02, 127.49, 60.16, 57.82, 
53.33, 52.60, 36.31, 28.29, 27.96, 9.74. HRMS (ESI-TOF) m/z calcd for C21H26N2O 
[M+H]
+
:323.2118. Found 323.2117. 
N-((1-(3-hydroxybenzyl)pyrrolidin-3-yl)methyl)-N-phenylfuran-2-carboxamid (34): 
The title compound was prepared from N-(pyrrolidin-3-ylmethyl)-1H-indole-2-carboxamide 3.3 
(73mg, 0.205 mmol) and 3-hydroxybenzaldehyde ( 0.185 mmol, 25.6 mg) according to 
procedure A. Crude product was purified on silica gel chromatography (CH2Cl2/ MeOH, 98:2) to 
afford 34 as a yellow oil (59mg, 58% ). 
1
H NMR (400 MHz, Chloroform-d) δ 7.35 (dd, J = 5.1, 
2.2 Hz, 3H), 7.28 (dd, J = 1.8, 0.8 Hz, 1H), 7.12 – 7.10 (m, 2H), 7.07 (t, J = 7.8 Hz, 1H), 6.95 (t, 
J = 2.0 Hz, 1H), 6.72 (dd, J = 7.5, 4.1 Hz, 2H), 6.13 (dd, J = 3.6, 1.7 Hz, 1H), 5.60 (d, J = 3.6 
Hz, 1H), 4.13 – 4.07 (m, 1H), 3.70 (dd, J = 13.3, 6.7 Hz, 2H), 3.52 (d, J = 13.1 Hz, 1H), 2.71 – 
2.68 (m, 2H), 2.55 (dd, J = 9.8, 6.2 Hz, 1H), 2.49 (q, J = 7.5 Hz, 1H), 1.95 – 1.87 (m, 1H), 1.55 
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(dd, J = 13.0, 6.3 Hz, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 159.55, 157.13, 146.59, 
144.60, 141.86, 129.71, 129.40, 128.35 (d, J = 2.1 Hz), 120.21, 116.76, 116.38, 114.95, 111.05, 
59.48, 57.12, 53.46, 53.33, 35.80, 27.94. HRMS (ESI-TOF) m/z calcd for C23H24N2O3 
[M+H]
+
:377.1860 Found 377.1868. 
N-((1-(4-hydroxybenzyl)pyrrolidin-3-yl)methyl)-N-phenylfuran-2-carboxamide (35): 
1
H NMR (400 MHz, Chloroform-d) δ 7.37 (dd, J = 5.2, 2.1 Hz, 2H), 7.31 (d, J = 1.7 Hz, 1H), 
7.15 (d, J = 3.8 Hz, 2H), 7.13 (d, J = 1.8 Hz, 1H), 7.09 (d, J = 8.0 Hz, 2H), 6.66 (d, J = 8.0 Hz, 
2H), 6.16 (dd, J = 3.5, 1.7 Hz, 1H), 5.63 (d, J = 3.6 Hz, 1H), 3.99 (dd, J = 13.4, 8.0 Hz, 1H), 3.84 
(dd, J = 13.5, 6.8 Hz, 1H), 3.65 (s, 2H), 2.99 (t, J = 8.8 Hz, 1H), 2.86 (d, J = 8.8 Hz, 1H), 2.67 
(d, J = 8.4 Hz, 1H), 2.62 – 2.54 (m, 1H), 2.49 (d, J = 9.0 Hz, 1H), 2.02 – 1.92 (m, 1H), 1.66 – 
1.57 (m, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 159.75, 157.01, 146.72, 144.77, 142.12, 
130.99, 129.92, 128.55, 128.44, 116.96, 115.95, 111.24, 59.68, 57.57, 53.62, 53.07, 36.21, 28.16. 
HRMS (ESI-TOF) m/z calcd for C23H24N2O3 [M+H]
 +
:377.1860. Found: 377.1868 
N-((1-phenethylpyrrolidin-3-yl)methyl)-N-phenylfuran-2-carboxamide (36): 
1
H 
NMR (400 MHz, Chloroform-d) δ 7.43 – 7.37 (m, 3H), 7.32 (d, J = 1.7 Hz, 1H), 7.27 (dd, J = 
8.2, 6.8 Hz, 2H), 7.19 (td, J = 6.3, 1.7 Hz, 5H), 6.17 (dd, J = 3.6, 1.8 Hz, 1H), 5.68 (d, J = 3.6 Hz, 
1H), 3.99 – 3.89 (m, 2H), 2.78 (ddd, J = 9.0, 7.3, 2.0 Hz, 3H), 2.67 (dddd, J = 15.9, 12.6, 6.6, 2.7 
Hz, 3H), 2.60 – 2.48 (m, 3H), 2.35 (dd, J = 9.2, 6.8 Hz, 1H), 1.98 – 1.89 (m, 1H), 1.62 – 1.54 (m, 
1H). 
13
C NMR (101 MHz, Chloroform-d) δ 159.46, 147.18, 144.40, 142.55, 140.57, 129.68, 
128.74, 128.53, 128.44, 128.20, 126.08, 116.38, 111.03, 58.43, 58.29, 54.09, 53.91, 36.32, 35.72, 
28.59. HRMS (ESI-TOF) m/z calcd for C24H26N2O2 [M+H]
 +
:375.2067. Found: 375.2067 
N-benzyl-N-((1-benzylpyrrolidin-3-yl)methyl)furan-2-carboxamide (37): 
1
H NMR 
(400 MHz, DMSO-d6) δ 7.79 (s, 1H), 7.33 – 7.18 (m, 10H), 7.01 (s, 1H), 6.58 (s, 1H), 3.53 (s, 
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4H), 2.55 – 2.33 (m, 5H), 2.30 – 2.21 (m, 1H), 1.82 – 1.75 (m, 1H), 1.35 (s, 1H). 13C NMR (101 
MHz, DMSO-d6) δ 160.39, 147.74, 145.16, 139.16, 137.97, 128.98, 128.92, 128.58, 127.59, 
127.30, 116.24, 111.81, 59.72, 57.53, 53.37, 36.21, 28.13. . HRMS (ESI-TOF) m/z calcd for 
C24H26N2O2 [M+H]
+
:375.2067. Found 375.2045 
N-benzyl-N-((1-phenethylpyrrolidin-3-yl)methyl)furan-2-carboxamide (38): 
1
H 
NMR (400 MHz, DMSO-d6) δ 7.78 (d, J = 1.7 Hz, 1H), 7.29 – 7.25 (m, 7H), 7.20 (s, 3H), 6.96 
(d, J = 3.5 Hz, 1H), 6.57 (dd, J = 3.5, 1.8 Hz, 1H), 3.67 (t, J = 17.4 Hz, 4H), 3.57 (d, J = 9.4 Hz, 
2H), 3.50 (d, J = 6.4 Hz, 2H), 2.56 (dd, J = 16.0, 6.8 Hz, 4H), 2.33 (s, 1H), 1.89 – 1.82 (m, 1H), 
1.41 (s, 1H).. 
13
C NMR (101 MHz, DMSO-d6) δ 159.89, 148.29, 144.79, 139.47, 129.10, 128.81, 
128.53, 127.19, 126.67, 115.91, 111.73, 59.87, 57.56, 55.31, 53.44, 36.50, 28.19. HRMS (ESI-
TOF) m/z calcd for C25H28N2O2 [M+H]
+
:389.2224. Found 389.2212. 
Ethyl 1-benzyl-4,4-bis(trifluoromethyl)pyrrolidine-3-carboxylate (4.3): Under an 
argon atmosphere, to a stirred solution of dry azomethine ylide precursor 4.2 (640 mg, 2.092 
mmol) and a dipolarophile (326mg, 1.312 mmol) in DCM (2mL) was slowly added 
trimethylsilyl trifluoromethanesulfonate (75 µL). The resulting reaction mixture was stirred 
under argon at room temperature overnight, followed by dilution with DCM and saturated 
NaHCO3. The layers were separated, the aqueous layer was extracted with DCM, and the 
combined organic phases were washed with brine, dried over MgSO4, and concentrated in vacuo. 
Purification by flash chromatography (1:50 EtOAc/hexanes to 1:40 EtOAc/hexanes) gave 
compounds 4.2 colorless oils in 68% yield. 
1
H NMR (400 MHz, Chloroform-d) δ 7.37 (d, J = 4.3 
Hz, 4H), 7.33 – 7.29 (m, 1H), 4.24 (ddp, J = 14.3, 7.2, 3.6 Hz, 2H), 3.77 (d, J = 13.1 Hz, 1H), 
3.64 (d, J = 13.1 Hz, 1H), 3.47 – 3.42 (m, 1H), 3.39 (d, J = 11.2 Hz, 1H), 3.22 (t, J = 8.3 Hz, 
1H), 2.90 (t, J = 10.2 Hz, 1H), 2.73 (d, J = 11.2 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H). 
13
C NMR (101 
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MHz, Chloroform-d) δ 168.05, 137.82, 128.67, 128.50, 127.62, 61.71, 59.07, 56.42, 55.91, 
46.25, 13.86. 
Prepare of 1-benzyl-N-phenyl-4,4-bis(trifluoromethyl)pyrrolidine-3-carboxamide 
(4.4). Ethyl 1-benzyl-4,4-bis(trifluoromethyl)pyrrolidine-3-carboxylate  (1g, 2.71 mmol)was 
dissolved in a 1:1:2 mixture of THF/EtOH/1 M aqueous NaOH, total volume of 12 mL. This was 
stirred at 60°C for 5 h. The mixture was allowed to cool, and the organic solvents in the mixture 
were mostly removed by rotary evaporation. The pH was then reduced by addition of 
concentrated HCl to ∼ pH 4, and the resulting white precipitate was collected over a filter to give 
the desired carboxylic acid (802mg, 87%). 
1
H NMR (400 MHz, Methanol-d4) δ 7.65 (d, J = 3.9 
Hz, 2H), 7.53 – 7.51 (m, 3H), 4.59 (d, J = 15.3 Hz, 2H), 4.25 (s, 1H), 4.02 (s, 1H), 3.92 (t, J = 
5.9 Hz, 1H), 3.85 (d, J = 7.1 Hz, 1H), 3.73 (d, J = 11.6 Hz, 1H). 
13
C NMR (101 MHz, Methanol-
d4) δ 167.90, 129.36, 128.55, 128.50, 58.50, 55.01 (d, J = 9.8 Hz), 45.21. 
Without further purification 1-benzyl-4,4-bis(trifluoromethyl)pyrrolidine-3-carboxylic 
acid (200 mg, 0.586 mmol), DIEA (0.0.31 mL, 1.74 mmol), EDCI (124.09 mg, 0.655 mmol), 
HOBt (96.5 mg, 0.654 mmol), and finally aniline (0.11mL, 0.868 mmol). This was stirred at rt 
for 16 h, at which time the material was partitioned between saturated NaHCO3 solution and 
EtOAc, and the organic layer was washed with saturated solution of NaCl. The organic layer was 
dried with anhydrous MgSO4.Filtered and concentrated in vacuum. Purification was 
accomplished via flash chromatography (5/95 : EtOAc/Hex) to give the desired product 4.5 (162 
mg, 66.3%).
1
H NMR (400 MHz, Chloroform-d) δ 7.58 – 7.56 (m, 2H), 7.43 – 7.39 (m, 2H), 7.29 
– 7.22 (m, 5H), 7.21 (d, J = 7.4 Hz, 1H), 3.83 (d, J = 12.8 Hz, 1H), 3.69 (d, J = 12.8 Hz, 1H), 
3.42 (t, J = 5.7 Hz, 1H), 3.26 (d, J = 11.2 Hz, 1H), 3.20 (dd, J = 9.9, 5.2 Hz, 1H), 3.09 (d, J = 
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11.2 Hz, 1H), 2.93 (dd, J = 9.8, 6.3 Hz, 1H). 
13
C NMR (101 MHz, Chloroform-d) δ 165.82, 
146.78, 137.32, 129.10, 128.87, 128.66, 127.96, 124.77, 120.35. 
N-((1-benzyl-4,4-bis(trifluoromethyl)pyrrolidin-3-yl)methyl)aniline (4.5). Amide 
IV.b 162mg (0.389 mmoles) in THF 3mL was added dropwise to a suspension of LAH (90mg 
2.4 mmoles) in THF 3 mL at 0 
o
C. after the addition was complete, the reaction mixture was 
refluxed for 18 h, cooled to 0 
o
C, and quenched carefully by addition 0.1mL H2O then 0.1mL of 
15% NaOH finnaly 0.3mL H2O. The resulting white precipitate was removed by filtration, and 
the filtered was transferred to a separatory funnel. The layers were separated, and the aqueous 
layer was extracted with EtOAc. The organic extract and layer were combined, dried (NaSO4), 
and concentrated. Solution dried by evaporated under reduced pressure to give 0.138 g of amine 
4.5. (88% yield). 
 N-((1-benzyl-4,4-bis(trifluoromethyl)pyrrolidin-3-yl)methyl)-N-phenylfuran-2 
carboxamide (39): Under argon atmosphere 80 mg (0.161 mmoles) of 4.6 were dissolved in dry 
CH2Cl2 (7mL) and under vigorously stirring Et3N ( 0.69 mmoles, 0.1 mL Et3N) was added at 0
 
o
C. then a solution of furan-2-carbonyl chloride (0.23 mmoles, 30 mg) in anhydrous CH2Cl2 (2 
mL) was slowly added. The mixture was stirred at room temperature for 12h. The reaction 
mixture was treated with 1N HCl. The organic layer was isolated and washed with NaHCO3 
saturated aqueous solution and then with H2O until neutral PH. The organic layer was dried with 
anhydrous MgSO4, and concentrated in vacuum. Purification by flash chromatography (0.5:99.5 
MeOH/DCM to 1:99 MeOH/DCM) give compounds 39 colorless oils in 38% yield. 
1
H NMR 
(400 MHz, Chloroform-d) δ 7.44 – 7.40 (m, 3H), 7.32 – 7.29 (m, 6H), 7.19 (dd, J = 6.1, 2.0 Hz, 
2H), 6.20 (dd, J = 3.6, 1.8 Hz, 1H), 5.82 (d, J = 3.6 Hz, 1H), 4.58 (d, J = 12.5 Hz, 1H), 3.91 (d, J 
= 2.9 Hz, 1H), 3.84 (s, 1H), 3.47 (d, J = 13.2 Hz, 1H), 3.27 (s, 2H), 3.25 (d, J = 5.5 Hz, 1H), 2.97 
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(dd, J = 7.2, 3.3 Hz, 1H), 2.65 (d, J = 10.0 Hz, 1H), 2.56 (s, 1H). 
13
C NMR (101 MHz, 
Chloroform-d) δ 159.58, 146.87, 144.74, 142.23, 137.96, 129.96, 128.61, 128.47, 127.96, 
127.45, 116.96, 111.21, 59.30, 58.67, 55.77, 48.69, 41.92. . HRMS (ESI-TOF) m/z calcd for 
C25H22F6N2O2[M+H]
+
:361.1911. Found 361.1912. And calcd for [M-H]
+
 497.1658. Found 
497.1662 
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CHAPTER TWO 
II.1 INTRODUTION 
1.1Historical Perspective on Natural Products and Traditional Medicine 
Natural products have been used for medicinal, recreational, and ritualistic purposes 
throughout recorded history. Various ancient civilizations have left written evidence of 
significant ethnomedical practices. Cuneiform tablets from around 650 BC describe the 
extensive pharmacopeia of ancient Mesopotamia, with over 100 medicines from mineral 
sources and approximately 250 derived from plant sources [208]. The information contained in 
many of these cuneiform tablets was copied from even earlier sources dating to 2000-3000 BC. 
One example of a ritualistic use of natural products comes from the Rigveda text from ancient 
India, which describes soma, an inebriant from plant sources [209-210]. China also has a long 
history of traditional medicine dating back some 4000 years to the Shang dynasty [211]. Some 
of the best known ethnomedical products from China are ephedra and ginseng. These have been 
used for millennia to treat a wide variety of conditions, ranging from asthma to incontinence. 
Chinese ethnomedical tradition is well documented and preserved, with more than 10,000 
known medicinal substances [211]. America has its own history of natural products use for 
ritual purposes. The Toltec people of Central America utilized teonanácatl and the widely-
known peyote for their mind-altering properties [212]. Another example of a well-documented 
ethnomedical history is De material medica, written by Dioscorides, a Greek physician who 
worked for the Roman military in the first century AD [213]. He documented hundreds of 
different plants used for various medical purposes in a five-volume codex. This was one of the 
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few classical works which continued to be circulated during the middle ages, between the 5
th
 
and 14
th
 centuries AD, and thus became a widely recognized authority on medicine, 
pharmacology, and ethnomedicine all the way up until the 16
th
 century. 
According the World Health Organization (WHO), up to 80% of the population in some 
developing nations still relies on traditional medicine, despite the rise of modern medicine and 
pharmacology [214]. Various forms of traditional medicine remain popular in some developed 
countries as well. A 2007 CDC survey showed that 17.7% of adult Americans have used natural 
products such as fish oil, Echinacea, ginseng, or glucosamine to promote health through 
complimentary/alternative medicine [215].  
1.2 Opioids: Natural Products used in Modern Medicine 
Opioids are also an example of a natural product used in medicine. Opioid drugs are 
known as analgesics, because of their ability to relieve pain [68]. Other names for pain-
relieving drugs are analgetics and antinociceptives. While in modern medicine NSAIDs are 
used for mild to moderate pain, opioid drugs are used for persistent or severe pain [7]. Opioids 
have a long history of use as pain relievers, beginning thousands of years ago with use of poppy 
extracts. An Egyptian papyrus from 1552 BC documents the use of poppy extracts for pain 
management, with the account of the goddess Isis treating the sun god Ra with a poppy extract 
for his headache [216].  
The use of opioid analgesics to treat severe, chronic cancer and non-cancer related pain is 
currently standard medical practice, but is not without controversy [7,216]. Although in the 1960s, 
use of opioid drugs to treat chronic pain was reduced, in the 1970s New York’s Sloan Kettering 
Hospital and St. Christopher’s hospital in London returned to the use of opioids for the 
management of pain in cancer patients [216]. The American Geriatric Society recommended in 
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2009 that opioid analgesics be used to treat patients with moderate to severe pain or diminished 
quality of life [217]. Chou et al, together with the American Academy of Pain and the American 
Pain Society also recommended in 2009 that opioid drugs be used, under close supervision, to 
treat non-cancer patients with chronic pain [218].  
The reason for the debate over the use of opioid analgesics is the severe side effects 
caused by these drugs, including respiratory depression, constipation, tolerance, and 
dependence [7,78]. Despite these problems, opioid drugs continue to be one of the primary 
methods of treating pain. The opioid analgesics most commonly used in the clinical setting are 
morphine, codeine (1), oxycodone (2), meperidine (3), fentanyl (4), methadone (5), and 
Propoxyphene (6) was used until November 2010, when it was discontinued in the US because 
of patient deaths due to its cardiotoxic effects (Figure 52) [7- 219]. 
Figure 52. Clinically used opioids. 
 
116  
1.3 Introduction to Flavonoids 
Flavonoids are another type of natural product with a variety of modern medicinal and 
pharmacological uses [220-222]. These polyphenolic natural products are useful for their free-
radical scavenging activities as well as anti-cancer, anti-inflammatory, and anti-oxidant 
properties. Flavonoids are known to chelate bivalent metals and block redox cycling. They have 
also been shown to inhibit a variety of kinases, enzymes responsible for prostaglandin 
biosynthesis, and topoisomerase I and II, as well as bind to the estrogen receptor [221]. 
Flavonoids are derived mainly from fruits and vegetables, soybeans, tea leaves, and herbs [221]. 
Due to the fact that they are produced by a variety of plants, flavonoids are widely available in 
foods and other edible plant products, making them more likely than other scaffolds to have 
acceptable side effect and toxicity profiles [223]. For this reason, flavonoids are an attractive 
focus for natural products research. 
A flavonoid molecule is built around the flavan core (8) consisting of 15 carbon atoms 
arranged in the A, B, and C rings [224]. The first step to synthesizing flavonoids is condensing 
one 4-coumaroyl CoA (12) molecule with three molecules of malonyl CoA, which yields 
chalcone, a flavonoid precursor (scheme 6) [221]. 4-coumaroyl CoA is produced by 
deanimating phenylalanine (9) with phenylalanine ammonialyase, then hydroxylating the 
resulting trans- cinnamate product (10) with cinnamate 4-hydroxylase, a cytochrome P450 
(CYP450) enzyme, to produce 4-coumarate [225]. 4-Coumarate: CoA ligase catalyzes the 
activation of 4-coumarate to the CoA thioester, producing the precursor 4-coumaroyl CoA (12). 
Hydroxylation of 4-coumaroyl CoA at the 3 position by 4-coumaroyl CoA 3-hydroxylase yields 
caffeoyl CoA (13), another precursor found in some plant species. Condensation of acetyl CoA 
and CO2, facilitated by acetyl CoA carboxylase, results in malonyl CoA. Next, 2’,4’,6’,4-
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tetrahydroxychalcone (14) is produced by the stepwise condensation of 4-coumaroyl  CoA and 
three malonyl CoA molecules, catalyzed by the enzyme chalcone synthase. Stereospecific 
cyclization of the chalcone precursor, which is catalyzed by chalcone isomerase results in a 2S-
flavonone naringenin (15), possessing the basic flavonoid skeletal core. This 2S-flavonones are 
simple scaffolds which can be modified considerably using different enzymes to produce a wide 
variety of structures with diverse biological activities. 
Scheme 6. Biosynthetic pathway of flavonoids
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Flavonoids are classified based on the structures of their carbon skeletons. There are 
eight flavonoid groups: flavans (8), flavanones (16), flavones (17), chalcones (18). 
isoflavanones (19), and isoflavones (20) [221]. Flavanoids are generally assigned as 
phytoestrogens, due to the similarity between their structures and biological activities, and those 
of naturally occurring estrogens [226]. With more than 8000 known flavonoid compounds, their 
seemingly universal presence, extensive array of biological activities, and ease of synthesis 
makes them a prime target for research on new disease pharmacotherapies [224]. 
Figure 53. Classification of flavonoids. 
 
1.4 The Identification of Flavonoids as Potential Opioid Receptor Ligands  
The potential for flavonoids as a source for novel opioid receptor ligands was first 
described by Prisinzano [227] when they showed that amentoflavone (21), a biflavone found in 
H. perforatum extracts, competes for binding to opioid receptors. It has a high affinity for the  
receptor and shows antagonist activity at both the  and  receptors. Amentoflavone was the first 
flavonoid to have demonstrated  antagonist properties. This discovery opened up the possibility 
of using the flavonoid scaffold to develop opioid antagonist and other opioid ligands. Based on 
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this finding, they evaluated a number of different natural products to test the effects of changes 
to the flavonoid core [227]. Among the flavonoids tested were apigenin (22), hyperoside (23), 
4’-hydroxyflavonone (24), (+)-catechin (25), (-)- epigallocatechin (26), and (-)-catechin gallate 
(27). Each of these flavonoid compounds showed some level of potency at the  and  receptors, 
but no significant potency at the  receptor [227]. This demonstrates that flavonoids have 
potential for researchers looking to develop molecules that show opioid receptor activity but 
have low shape similarity to opioid ligands.  
A flavonoid that shows selective agonist activity at the  receptor is casticin 28, which is 
a taxonomical marker for the Vitex genus [228]. Research using animal models showed that C-
glycosylated flavone vitexin 29 produced anti-nociceptive effects caused by an opioid 
mechanism involving all three receptor types [229]. 
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Figure 54. Selected flavonoids screened in the [
35
S]GTP-γ-S functional assay. 
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II.2 RESULT AND DISCUSSION 
2.1 Perovskia Atriplicifolia Background  
Perovskia atriplicifolia, more commonly known as Russian Sage, is a silver-grey shrub 
reaching about 1.5 meters high and comprised of airy spires that bear small, edible lavender 
flowers. The plant is native to the rocky areas of Central Asia, including, Pakistan, Afghanistan, 
Iran, and Tibet. It is mainly known for its ornamental and flavoring qualities. It is also smoked as 
a euphoriant and used as a decoction for chronic dysentery [230]. Recently, the Russian Sage 
plant has been explored as a possible remediative plant as a means to improve air and soil quality 
[231]. The ethanolic extract of Russian Sage leaves was found to have a percent displacement 
between 40 to 50 % for the opioid receptors. 
Herein, we report the phytochemical study of the ethanolic extract of P. atriplicifolia 
leaves following a bioassay-guided fractionation strategy. Four previously known compounds, 
namely, 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (1), 5,7-dihydroxy-3’,4’,6,-trimethoxy 
flavone (2), 5-hydroxy-4’,6,7-trimethoxy flavone (3) and 5,7-dihydroxy-4’,6-dimethoxy flavone 
(4), were isolated, structurally elucidated and  evaluated for their radioligand affinity on opioid 
and cannabinoid receptors (Figure 55). 
2.2 Biologically active compound from Perovskia atriplicifolia 
The crude ethanol extract obtained from the leaves of P. atriplicifolia was fractionated on a flash 
silica gel column in a polarity gradient, resulting in five fractions: hexane (I), dichloromethane 
(II), ethyl acetate (III), ethyl acetate:methanol 8:2 (IV) and methanol (V). Fractions (I) to (V) 
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were tested for their biological activity. Fraction (III) showed 46.0% and 88.4 % radioligand 
binding displacement for CB2 and δ opioid receptors, respectively (Figure 56). Accordingly, 
Fraction (III) was subsequently chromatographed on reversed phase silica gel C18 column 
initially with water and stepwise elution to MeOH, yielding six subfractions (water (A); 80:20 
H2O–MeOH (B); 60:40 H2O–MeOH (C); 40:60 H2O–MeOH (D); 20:80 H2O–MeOH (E); and 
MeOH (F)), and the subfractions were subjected to the radioligand displacement bioassays. 
Subfraction D (40:60 H2O–MeOH) and subfraction E (20:80 H2O–MeOH) displayed a high 
percentage of radioligand displacement for the δ opioid receptor with values of 62.4 % and 78.5 
%, respectively. Subfraction D and E were subjected to further chromatographic separations to 
identify their active components.  
The chemical structures of the major components isolated from subfractions D and E 
were identified as 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (1), and 5,7-dihydroxy-3’,4’,6,-
trimethoxy flavone (2) from E; and 5-hydroxy-4’,6,7-trimethoxy flavone (3) and 5,7-dihydroxy-
4’,6-dimethoxy flavone (4) from D, using 1D and 2D NMR spectroscopic methods and mass 
spectrometry. 1H and 13C NMR spectroscopic data were compared with previously reported 
data and found to be consistent [232-234]. 
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Figure 55. Structure of flavonoids isolated from P. atriplicifolia
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All pure compounds (1-4) were submitted for in vitro radioligand binding affinity assays 
using opioid receptors (subtype, , and ) and cannabinoids receptors (CB1 and CB2) 
following the methods described previously with slight modifications [235]. The results are 
shown in Table 1. At a concentration of 10μM compounds 1, 3, and 4 selectively displaced the 
radioligand by 86.0 %, 31.6 % and 79.9 %, respectively, of the specific binding of [Tyrosyl-2, 6-
3
H(N)]-Enkephalin (2-D-Penicillamine, 5-D-Penicillamine) to HEK293 cell membranes 
expressing human δ–opioid receptor (Table 4). The Ki (3.1, 24.8 and 8.4 μM, for 1, 3, and 4, 
respectively) values are shown in Figure 57. In contrast, compound 2, a closely related flavonoid, 
showed low radioligand binding displacement at 10 μM with an affinity of only 19.9% for the δ–
opioid receptor. 
Table 4.  
Displacement radioligand assay of the isolated compounds (1-4) for human opioid receptors 
(subtype δ, κ and μ) and cannabinoid receptors (subtype CB1 and CB2), nt = not tested. 
 
 
 
 
 
 
This discovery spurred our investigation of the flavonoids 1-4 interactions with the 
human δ–opioid receptor using molecular modeling algorithms. We docked compounds 1-4 into 
the binding pocket of the known crystal structure complex of the mouse δ–opioid. The complex 
contains the morphinan analogue, naltrindole, which allowed us to better define the binding 
 
Compound 
        Opioid Receptors (%)  Cannabinoid Receptors (%) 
Δ κ Μ CB1 CB2 
1 86.0 7.5 9.5 3.0 4.2  
2 19.9 9.6 24.3 0.3 12.5 
3 31.6 7.4 -- 1.7 8.3 
4 79.9 -- 20.1 19.3 13.5 
Extract 42.8 37.6 52.2 12.2 26.8 
Naloxone 106.40 101.59 96.95 Nt Nt 
CP 55,940 Nt nt Nt 104.3 102.6 
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pocket [236] Compounds 1 and 4 showed good docking scores (-8.6 and -8.4 kcal/mol, 
respectively) compared to compounds 2 and 3 (-7.8 and -7.7 kcal/mol, respectively), which 
correlate with the experimental activities (compounds 1 and 4 are more active than compounds 2 
and 3). Compound 4 (Figure 58) forms H-bonds with the key amino acids Tyr308, His278, and 
Tyr129 and shows interactions with hydrophobic residues Met132, Val217, Phe218, Phe222, and 
Trp274. Similar interactions are observed in the case of compound 1. One of the main questions 
was the apparent contradiction between the structural similarity of compounds 3 and 4, and their 
difference in inhibitory values (Table 1). A minor structural modification of compound 4 through 
conversion of the 7-hydroxyl to a methoxy group, leads to a decrease in the inhibitory potential 
(cf. compound 3). The same structural effects on activity are found in the case of compounds 1 
and 2. These observations can be explained, in part, by taking into consideration the 
thermodynamic properties of the active site in the apo-form (unbound protein). The active site 
shows two distinct regions of free energy, which affect the ligands binding and hence distinguish 
between their biological activities. Figure 59 shows the negative free energy regions (blue), 
which support polar substituents, surround the polar hydroxyl groups of compound 4, as well as, 
the hydrophobic regions of the compound are well fitted inside the positive regions (red) (Figure 
59).  
Based on the structural features of the flavones and the thermodynamic properties of the 
active site, we can explain the reason behind the activity of compound 1. By adding methoxy 
groups at positions 7 and 3`, the binding mode of compound 1 will adjust itself to compensate for 
the hydrophobicity of the 7-methoxy group, however this will lead to the 4-methoxy being 
orientated in an unfavourable region. Furthermore, 3-methoxy will fit very well in the positive 
free energy region, which in turn will compensate for the unfavourable positioning of the 4-
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methoxy. Compound 3 will have close behaviour to compound 1 by adjusting the location of ring 
A in the active site, but on the other hand there is no compensatory effect as that is found in 
compound 1, which could explain its weak binding affinity to the active site. Compound 2 will 
follow the same pattern of compound 4, but ring B will be in the unfavourable region revealing 
this as a possible cause of the lower inhibitory potential of compound 2. 
In conclusion, four known flavones 1-4 were isolated using bioassay-guided 
fractionation. The potency of compounds 1 and 4 binding to the δ opioid receptor subtype further 
suggest that flavonoids may be used as leads for opioid receptor ligands. Also, this report 
illustrates why P. atriplicifolia is used as a euphoriant. Further studies are needed to explore the 
mechanism of action of the isolated secondary metabolites, and to conduct additional 
phytochemical studies on P. atriplicifolia. 
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Figure 58 . 
Top: The protein complex: protein is shown as yellow cylindrical helices, red sheets and green loops. The 
ligand is shown as ball and sticks. Botton: The interaction profile model of compound 4: the amino acid 
residues in range of 5 Å of the ligand are shown as sticks, hydrogen bonds are shown as dotted lines (cyan 
for hydrogen bond donor and yellow for hydrogen bond acceptor).
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Figure 59.  
Molecular surface of the active site of δ opioid receptor pocket showing zones of negative free energy as 
blue surface and positive free energy as red, docked with the compounds 1-4.
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II.3 EXPERIMENTAL SECTION 
General Experimental Procedures. 
1
H and 
13
C NMR spectra were obtained on Bruker 
model AMX 500 and 400 NMR spectrometers with standard pulse sequences, operating at 500 
MHz in 
1
H and 125 MHz in 
13
C. CDCl3, DMSO-d6, and CD3OD were used as solvents and TMS 
was used as internal standard. High-resolution mass spectra (HRMS) were recorded on a 
Micromass Q-Tof Micro mass spectrometer with a lock spray source. Column chromatography 
was carried out on silica gel (70-230 mesh, Merck) and Sephadex LH-20 (GE Healthcare, 
Uppsala, Sweden). Fractions obtained from column chromatography were monitored by TLC 
(silica gel 60 F254). Preparative TLC was carried out on silica gel 60 PF254+366 plates (20 × 20 
cm, 1 mm thick). All chemicals used were from Sigma-Aldrich (Poole, Dorset, U.K.) with the 
following exceptions. For the binding experiments, [
3
H]CP 55,940 (174.8 Ci/mmol), 
[
3
H]DAMGO (53.4 Ci/mmol), [
3
H]U-69,593 (42.7 Ci/mmol), [
3
H]Enkephlin (45 Ci/mmol), were 
obtained from Perkin-Elmer Life Sciences Inc. (Boston, MA, U.S.A.). CP 55,940, DAMGO, 
DPDPE, nor-Binaltorphimine and Win 55,212-2 were obtained from Tocris Bioscience 
(Ellisville, Missouri, U.S.A.). 
Plant Material. The plant, Perovskia atriplicifolia, was collected in the region of Quetta, 
Pakistan in July of 2012 and identified by Dr. Mudassir Asrar from the Medicinal Plant Garden 
at the University of Balochistan, Quetta, Pakistan. A voucher specimen (121/5, HBG/UOB) has 
been deposited in the Herbarium of Botanical Garden, Quetta, Pakistan. A voucher specimen is 
also in the culture collection of the Department of BioMolecular Sciences, University of 
Mississippi. (UM 072012). 
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Extraction and Isolation. The dried leaves-plant material were ground into a powder 
yielding 370 g, the plant material was extracted with ethanol after maceration for three days. 
Removal of the solvent afforded a viscous residue (40 g). The ethanolic extract from the leaves 
showed moderate radioligand displacement binding affinity for opioid receptors (42.8% for δ and 
52.5% for μ). The ethanolic extract (39.0 g) was chromatographed on Si gel flash column with 
stepwise fractions from hexanes to methanol, yielding five fractions in five fractions: hexane (I), 
dichloromethane (II), ethyl acetate (III), ethyl acetate:methanol 8:2 (IV) and methanol (V). 
Fractions (I) to (V) were tested for their biological activity. The ethyl acetate fraction III showed 
strong binding affinities for δ opioid receptors (88.4%), this fraction was was subsequently 
chromatographed on reversed phase silica gel C18 column initially with water and stepwise 
elution to MeOH, yielding six subfractions (water (A); 80:20 H2O–MeOH (B); 60:40 H2O–
MeOH (C); 40:60 H2O–MeOH (D); 20:80 H2O–MeOH (E); and MeOH (F)), all subfractions 
were submitted for radioligand binding activity. Subfractions D and E showed strong binding 
affinities for δ opioid receptors with values of 62.8% and 78.5 %, respectively. Subfraction D 
(40:60 H2O–MeOH) was rechromatography in silica gel column eluted with hexane to ethyl 
acetate in step gradient to yield fifteen subfractions, D1 to D15. From the subfraction D10 and 
D12 a precipitate was obtained and crystallized separately to obtain flavones 1 (12 mg) and 2 (10 
mg). The subfraction E (20:80 H2O–MeOH) was rechromatography in silica gel column eluted 
with hexane to ethyl acetate in step gradient to yield thirteen subfractions E1 to E13. From 
subfractions E5 to E7 a precipitate was obtained. The solid showed two major spots using TLC 
plates and a 20% ethyl acetate in dichloromethane solvent system, the subfractions were 
combined and subject to a column of Sephadex LH-20 eluted with dichloromethane:methanol 
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(1:1) to furnish flavones 3 (5 mg) and 4 (3 mg) . All purified compounds were submitted for 
opioid receptor binding affinity. 
Cell Culture. HEK293 cells (ATCC) were stably transfected with cannabinoid receptor 
subtypes 1 and 2, (obtained from Origene, Rockville, MD, U.S.A.). These cells were maintained 
in a humidified incubator at 37 
o
C and 5% CO2 in a Dulbecco’s Modified Eagles’s medium 
(DMEM) nutrient mixture F-12 HAM supplemented with 2 mM L-glutamine, 10% fetal bovine 
serum, 1000 IU/mL Penicillin and 1000 g/mL of Streptomycin, and 0.5 mg/mL G418 antibiotic 
solutions. HEK293 cells stably transfected with opioid receptor subtypes µ, δ, and κ, were used 
to perform the opioid receptor binding assays. These cells were maintained at 37 
o
C and 5% CO2 
in a DMEM nutrient mixture supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 
1000 IU/mL Penicillin and 1000 g/mL of Streptomycin, and either 0.5 mg/mL () or 0.2 
mg/mL ( or ) G418 antibiotic solutions. Membranes for the radioligand binding assays were 
prepared by scraping the cells in cold Tris-HCl, pH 7.4 and then centrifuged at 5,200 x g for 10 
min at 4°C. The supernatant was discarded and the pellet was resuspended in the same buffer and 
homogenized via Sonic Dismembrator Model 100 (Fisher Scientific, Pittsburgh, PA) for 30 
seconds and then centrifuged at 1,000 x g for 10 min at 4°C. The supernatant was saved and the 
pellet underwent the suspension and sonication process 2 more times with the same conditions. 
The supernatants were combined and centrifuged at 23,300 x g for 40 minutes at 4°C. The pellet 
was re-suspended and aliquoted into 2mL vials and stored at -80°C. The total protein 
concentration was determined using a Pierce BCA Protein Assay Kit (Thermo Scientific, 
Rockford, IL) using to manufactures instructions [207].
 
The optimal membrane and radioligand 
(KD) concentrations for each receptor batch was established through a membrane evaluation and 
saturation binding experiments. 
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Radioligand Displacement for Cannabinoid Receptor Subtypes. Compounds 
evaluated in the assay were run in competition binding with both cannabinoid receptor subtypes, 
CB1 and CB2 [237].
 
Cannabinoid receptor binding screening were performed under the following 
conditions: 10 μM of each compound from independent triplicate dilutions was incubated with 
1.6975 nM(CB1) or 1.959 nM (CB2). [
3
H]-CP 55,940 a potent cannabinoid agonist with affinity 
for both receptor subtypes, and 5 μg CB1 or 1 μg CB2 membrane prepared in the above section 
was incubated for 90 minutes at 37 
o
C with gentle agitation in a 96-well plate in a 0.2 mL final 
volume of 50mM Tris-HCl, 20mM EDTA, 154mM NaCl and 0.2 % radioimmunoassay grade 
BSA, pH 7.4. The reaction was terminated via rapid vacuum filtration through Perkin Elmer 96-
well Unifilter GF/C filters (Perkin Elmer Life Sciences Inc., Boston, MA, U.S.A.) presoaked 
with 0.3% polyethylenimine, followed by 10 washes with 50 mM Tris-HCl, pH 7.4 buffer 
containing 0.2 % BSA. Plates were read using a Perkin Elmer TopCount NXT Microplate 
scintillation counter (Perkin Elmer Life Sciences Inc., Boston, MA. U.S.A.). Total binding was 
defined as binding in the presence of vehicle (1.0% DMSO). Nonspecific binding was the 
binding observed in the presence of 10.0 µM CP-55,940. Specific binding was defined as the 
difference between total and nonspecific binding. Percent displacement was calculated using the 
following formula: 100-(binding of compound- nonspecific binding)*100/specific binding.  
Radioligand Displacement for Opioid Receptor Subtypes. All compounds evaluated in 
the assay were run in competition binding against the opioid receptor subtypes (δ, κ, µ). Opioid 
binding assays were performed under the following conditions: 10 μM of each compound 
independent triplicate dilutions was incubated with 0.85 nM [
3
H]-DAMGO (µ), 0.91 nM 
[Phenyl-3,4-
3
H]- U-69,593 (κ), or 0.99 nM [3H]-enkephalin (δ) for 60 minutes in a 96-well plate 
in a 0.2 mL final volume of 50mM Tris-HCl, pH 7.4 with 15 μg () or 20 μg (µ and ) of 
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membrane. The reaction was terminated via rapid vacuum filtration through a Perkin Elmer 96-
well Unifilter GF/B filters presoaked with 0.3% BSA, followed by 10 washes with 50 mM Tris-
HCl, pH 7.4. Plates were read using a Perkin Elmer TopCount NXT Microplate scintillation 
counter. Total binding was defined as binding in the presence of vehicle (1.0% DMSO). 
Nonspecific binding was the binding observed in the presence of 10 μM DAMGO (µ), U-69,593 
(κ), or DPDPE (δ). Specific binding was defined as the difference between total and nonspecific 
binding. Percent binding was calculated using the following formula: 100-(binding of 
compound- nonspecific binding)*100/specific binding.  
The competitive binding assay was performed testing 12 triplicate 3-fold serial dilutions 
of 300 µM compound and 3 µM control (naloxone hydrochloride) with 15 µg of  membrane 
and 1.87 nM [
3
H]-DPDPE. The IC50 and Ki values were calculated by a non-linear curve fit 
model using GraphPad Prism 5.0 software (GraphPad, La Jolla, CA). 
Molecular Modelling and Docking Study. The protein structural file (PDB ID: 4EJ4) 
was downloaded from the protein databank (http://www.rcsb.org). The protein was subjected to 
an extensive structural preparation step to correct missing atoms, bond orders, tautomeric and 
rotameric states. We prepared the receptor grid using the coordinates of the bound ligand. Fred 
[238] module of the OpenEye software (www.eyesopen.com) was used for the docking step. All 
docking poses were then subjected to thermodynamic calculations using SZMAP [239]. The 
hydrogen atoms were explicitly added to the protein complexes and then, the partial charges 
were assigned. OH, S and Met-CH3 were allowed to rotate during the course of calculation. By 
using explicit water molecules as probes, SZMAP calculates the free energy of the active site 
surface.
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